Inhibition of the prostaglandin-degrading enzyme 15-PGDH to improve joint structure and function
Patent Information
- Application Number
- JP2023534973
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-09
- Filing Date
- 2021-12-09
- Publication Date
- 2024-12-05
AI Technical Summary
There are no effective disease-modifying drugs available for osteoarthritis, a chronic joint disease leading to significant disability, and existing treatments for joint tissue dysfunction and degeneration are limited, impacting quality of life through decreased mobility and chronic pain.
Administering a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor to inhibit its activity and reduce its levels, thereby increasing prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2) levels in joint tissues, improving joint tissue structure and function.
The method enhances joint tissue structure and function by reducing markers of dysfunction and degeneration, such as increased cartilage thickness, decreased fibrosis, and improved mitochondrial biogenesis, leading to reduced pain and improved joint function.
Abstract
Description
[Technical Field]
[0001] cross reference This application claims priority to U.S. Provisional Patent Application No. 63 / 123,061, filed on 9 December 2020, the disclosure of which is incorporated herein by reference in its entirety.
[0002] Description of the rights to inventions made under research and development funded by the federal government. This invention was developed with government support under Contract AG020961, awarded by the National Institutes of Health. The government has certain rights to this invention. [Background technology]
[0003] background Dysfunction and / or degeneration of joint tissues can have serious adverse effects on quality of life and normal function. Dysfunction and / or degeneration of joint tissues can be the result of aging, injury, disease, impairment, pathology, or other unexplained causes. For example, osteoarthritis is a chronic joint disease with increasing incidence and is a leading cause of physical disability affecting millions of people in the United States and around the world. However, there are no disease-modifying drugs available to treat osteoarthritis. Osteoarthritis, and other pathologies affecting the joints, can affect various joint tissues in different ways, leading to adverse effects such as reduced mobility, pain, and chronic pain.
[0004] Similar to osteoarthritis, treatment options for general dysfunction and / or degeneration of joint tissues are limited. Therefore, there remains a need in the art for effective strategies to improve the structure and / or function of joint tissues and thereby improve quality of life. This disclosure, in addition to other advantages, provides a method to satisfy this need. [Overview of the project]
[0005] overview This disclosure provides a method for improving the structure and / or function of joint tissue in a subject by administering an amount of a 15-PGDH inhibitor effective in inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity and / or reducing 15-PGDH levels in the subject. In some embodiments, the method includes a step of improving the structure of the joint tissue in the subject. In some embodiments, the method includes a step of improving the function of the joint tissue in the subject. In some embodiments, the administration increases the levels of prostaglandin E2 (PGE2) and / or prostaglandin D2 (PGD2) in the joint tissue in the subject. In some embodiments, the levels of PGE2 and / or PGD2 in the joint tissue increase compared to the joint tissue before administration of the 15-PGDH inhibitor. In some embodiments, the levels of PGE2 and / or PGD2 in the joint tissue increase (e.g., by at least about 10%) compared to the joint tissue before administration of the 15-PGDH inhibitor.
[0006] In some embodiments of the methods described herein, the joint tissue of the subject presents at least one marker of dysfunction and / or degeneration. In some embodiments, at least one marker is decreased GAG staining, decreased cartilage thickness, increased fibrosis, decreased smoothness of the cartilage surface, decreased bone tissue density, increased OARSI score, decreased sGAG level, decreased cell proliferation, increased pain and / or pain-related behavior in the subject, increased expression of Indian Hedgehog (Ihh) protein, increased expression of catabolic genes (e.g., matrix metalloproteinase (MMP)-13, MMP-3, MMP-1, aggrecanase, disintegrin and metalloproteinase 4 with a thrombospondin motif (ADAMTS4), ADAMTS5, cathepsin, or a combination thereof), decreased expression of anabolic chondrocyte genes (e.g., Sox9, collagen II, Acan, or a combination thereof), or increased expression of genes involved in mitochondrial function and metabolism. Selected from the group consisting of: a decrease in current, an increase in the expression of genes involved in mitochondrial dysfunction and / or osteoarthritis, a decrease in mitochondrial biosynthesis, a decrease in mitochondrial levels, an increase in type X collagen levels, an increase in chondrocyte size, an increase in chondrocyte sphericity, an increase in cytokine and / or chemokine levels (e.g., IL1, IL6, IL15, oncostatin M, tumor necrosis factor, or combinations thereof), an increase in inflammatory mediator levels (e.g., nitric oxide, reactive oxygen species, complement activation, or combinations thereof), an increase in cell-derived products and / or matrix-derived products (e.g., alarmin, e.g., S100, fibronectin fragments, hyaluronic acid fragments, collagen fragments, proteoglycan fragments, high-mobility group boxes, or combinations thereof), and combinations thereof. In some embodiments, administration reduces at least one marker of joint tissue dysfunction and / or degeneration. In some embodiments, the joint tissue dysfunction and / or degeneration in question is a result of aging.In some embodiments, the dysfunction and / or degeneration of the joint tissue in question is a result of injury (e.g., cartilage injury, joint injury, trauma, anterior cruciate ligament (ACL) rupture, meniscal tear, hip labral tear, rotator cuff injury, spondylosis, vertebral fracture, hip fracture, degenerative spondylolisthesis, slipped disc, herniated disc, and combinations thereof). In some embodiments, the dysfunction and / or degeneration of the joint tissue in question is a result of disease, disorder, or condition (e.g., osteoarthritis, other types of arthritis, osteoporosis, rheumatoid arthritis, juvenile idiopathic arthritis, gout, systemic lupus erythematosus, seronegative spondyloarthropathy, degenerative disc disease, congenital cartilage disorders, bone disorders, and combinations thereof). In some embodiments, the disease, disorder, or condition is osteoarthritis.
[0007] In some embodiments of the methods described herein, the levels of PGE2 and / or PGD2 in the joint tissue are increased to a level substantially similar to that present in the joint tissue of the subject that does not exhibit at least one marker of dysfunction and / or degeneration. In some embodiments, the levels of PGE2 and / or PGD2 in the joint tissue are increased to a level between 10% and 200% of the level present in the joint tissue of the subject that does not exhibit at least one marker of dysfunction and / or degeneration. In some embodiments, the joint tissue is selected from the group consisting of cartilage, synovial membrane, bone, bone marrow, ligaments, tendons, bursae, menisci, and combinations thereof.
[0008] In some embodiments of the methods described herein, the structure and / or function of joint tissue are improved compared to the joint tissue before administration of the 15-PGDH inhibitor. In some embodiments, the methods result in increased GAG staining, increased cartilage thickness, decreased fibrosis, increased smoothness of the cartilage surface, increased bone tissue density, decreased OARSI score, increased sGAG levels, increased cell proliferation, decreased pain and / or pain-related behavior in the subject, decreased expression of Indian Hedgehog (Ihh) protein, decreased expression of catabolic genes (e.g., MMP-13, MMP-3, MMP-1, aggrecanase, ADAMTS4, ADAMTS5, cathepsin, or combinations thereof), increased expression of anabolic chondrocyte genes (e.g., Sox9, collagen II, Acan, or combinations thereof), increased expression of genes involved in mitochondrial function and metabolism, and genes involved in mitochondrial dysfunction and / or osteoarthritis. This results in decreased gene expression, increased mitochondrial biosynthesis, increased mitochondrial levels, decreased levels of type X collagen, decreased chondrocyte size, decreased chondrocyte sphericity, decreased levels of cytokines and / or chemokines (e.g., IL1, IL6, IL15, oncostatin M, tumor necrosis factor, or combinations thereof), decreased levels of inflammatory mediators (e.g., nitric oxide, reactive oxygen species, complement activation, or combinations thereof), decreased levels of cell-derived products and / or matrix-derived products (e.g., alarmin, e.g., S100, fibronectin fragments, hyaluronic acid fragments, collagen fragments, proteoglycan fragments, high-mobility group boxes, or combinations thereof), or any combination thereof.
[0009] In some embodiments, the methods described herein result in a reduction in the levels of PGE2 and / or PGD2 metabolites in the joint tissue compared to the joint tissue before administration of the 15-PGDH inhibitor. In some embodiments, the methods result in levels of PGE2 and / or PGD2 metabolites in the joint tissue that are substantially similar to those present in the joint tissue of the subject that does not present with at least one marker of dysfunction and / or degeneration. In some embodiments, the PGE2 and / or PGD2 metabolites are selected from the group consisting of 15-ketoPGE2 and 13,14-dihydro-15-ketoPGE2.
[0010] In some embodiments of the methods described herein, the 15-PGDH inhibitor is selected from the group consisting of small molecule compounds, blocking antibodies, nanobodies, and peptides. In some embodiments, the 15-PGDH inhibitor is SW033291. In some embodiments, the 15-PGDH inhibitor is selected from the group consisting of antisense oligonucleotides, microRNAs, siRNAs, and shRNAs.
[0011] In some embodiments of the methods described herein, the subjects are human. In some embodiments, the subjects are under 30 years of age. In some embodiments, the subjects are at least 30 years of age. In some embodiments, the 15-PGDH inhibitor reduces or blocks 15-PGDH expression. In some embodiments, the 15-PGDH inhibitor reduces or blocks the enzymatic activity of 15-PGDH.
[0012] Other purposes, features, and advantages of this disclosure will be apparent to those skilled in the art from the following detailed description and figures. [Brief explanation of the drawing]
[0013] [Figure 1]This disclosure demonstrates that systemic inhibition of 15-PGDH by small molecules regenerates cartilage in aging mice. The top panel shows an experimental scheme for systemic inhibition of 15-PGDH, in which 24-month-old mice were treated intraperitoneally (ip) daily for one month with either a vehicle or the small molecule inhibitor of 15-PGDH SW0033291 (SW). Mice were evaluated after one month. The bottom left panel shows representative images of safranin O (Saf O) / Fast Green staining of the knee joints of aging mice after systemic treatment with the vehicle ("Aging VEH") or SW ("Aging SW"). The bottom right panel shows the maximum score ("MAX score") and summit score of the mouse knee joints of mice treated with the vehicle or SW, based on the OARSI scoring system. [Figure 2] This disclosure demonstrates that local 15-PGDH inhibition in the knee joint by intra-articular SW injection attenuates post-traumatic osteoarthritis (OA) in adult mice. The upper left panel shows the experimental scheme of tibial loading to induce OA in 3-month-old adult mice. Intra-articular injections of vehicle or SW were administered twice weekly for 4 weeks, and the joints were evaluated at 6 weeks after tibial loading. The upper right panel shows representative images of OA knee joints treated topically with vehicle or SW, stained with safranin O (SafO) / Fast Green. The lower left panel shows the maximum score ("MAX score") and summit score of mouse knee joints in mice treated with vehicle or SW, based on the OARSI scoring system. The lower right panel shows the significantly altered cytokine ratios obtained from the 48-plex Luminex assay between the vehicle-treated and SW-treated groups. The Welch t-test applied to statistical significance shows that * indicates P<0.05, *** indicates P<0.001, and **** indicates P<0.0001. [Figure 3]The aspects of this disclosure demonstrate that 15-PGDH inhibition alters multiple pathways for rejuvenating cartilage in aging mice. The heatmap shows differentially expressed genes identified by RNA sequencing and analysis in cartilage isolated from young (3-month) or aging (24-month) mice systemically treated with a vehicle ("Aging Veh") or SW ("Aging SW"). [Figure 4] This disclosure demonstrates that 15-PGDH inhibition enhances mitochondrial biosynthesis in aging cartilage. The upper panel shows representative TEM images of chondrocytes in articular cartilage of mouse joints from untreated young mice and aging mice systemically treated with a vehicle ("Aging Veh") or SW ("Aging SW"). For each mouse category, the upper panel shows magnified images of mitochondria in any group marked by a box in the lower panel. Scale bar = 2uM. The lower panel shows mitochondrial / cell quantification using Image J for the above categories. One-way ANOVA followed by multiple comparison tests were used to determine statistical significance. [Figure 5] This disclosure demonstrates that 15-PGDH inhibition induces a regenerative response in human OA cartilage explants. The upper left panel shows representative images of safranin O (SafO) / Fast Green staining of human OA cartilage explants (n>5) treated with vehicle ("control") or SW (10uM) for 7 days. The upper right panel shows the quantification of sulfated glycosaminoglycans (sGAGs) by 1,9-dimethylmethylene blue (DMMB) assay in OA cartilage explants (n=5) treated with vehicle ("CTRL") or SW (10uM). Statistical significance was determined by a paired t-test. The lower panel shows immunofluorescence images of Ki-67 staining of OA cartilage explants from three different donors treated with vehicle ("CTRL") or SW. [Figure 6]This disclosure demonstrates that 15-PGDH inhibition in human OA cartilage explants induces a regenerative response. The upper panel shows the quantitative distribution of Ki-67 staining intensity in OA cartilage explants in the vehicle-treated and SW-treated groups. The lower panel shows the significantly altered cytokine ratios obtained from the 80-plex Luminex assay between vehicle ("Veh")-treated and SW-treated OA explants from three different OA patients. Statistical significance was determined using the Welch t-test, where * indicates P<0.05, *** indicates P<0.001, and **** indicates P<0.0001. [Modes for carrying out the invention]
[0014] Detailed explanation 1. Introduction Osteoarthritis (OA) is a chronic joint disease with increasing incidence and is a leading cause of physical disability affecting millions of people in the United States and worldwide (Litwic et al., 2013, Br. Med. Bull. 105:185-199). There are no disease-modifying OA drugs available. Aging, trauma to articular cartilage, and chronic inflammation within the joint are molecular events associated with OA. The development of OA is multifactorial and is considered a whole-joint disease affecting cartilage, synovium, and bone, and the disease is influenced by age, sex, and metabolic status, in addition to genetic susceptibility.
[0015] Prostaglandin E2 (PGE2), also known as dinoprostone, is used in a variety of clinical applications, including inducing childbirth in women and enhancing hematopoietic stem cell transplantation. PGE2 can be used as an anticoagulant and antithrombotic agent. The role of PGE2 as a lipid mediator that can resolve inflammation is also well known. Nonsteroidal anti-inflammatory drugs (NSAIDs), which are inhibitors of cyclooxygenase 1 (COX-1) and / or cyclooxygenase 2 (COX-2), suppress inflammation by inhibiting prostanoids, primarily through PGE2 biosynthesis. Prostaglandin D2 (PGD2) is a structural isomer of PGE2, where the 9-keto and 11-hydroxyl groups on PGE2 are reversed on PGD2. PGD2 plays some role in many biological functions, including vasoconstriction, inflammation, regulation of body temperature during sleep, chemotaxis, and male sexual development. Both PGE2 and PGD2 are synthesized from arachidonic acid by cyclooxygenase (COX) and by prostaglandin E synthase or prostaglandin D synthase, respectively. The levels of PGE2 and PGD2 are physiologically regulated by the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which catalyzes the conversion of the 15-OH group in both PGE2 and PGD2 to a 15-keto group.
[0016] This disclosure is based in part on the discovery that inhibition of 15-PGDH inhibits degeneration of joint tissue (e.g., cartilage) and improves the structure and function of the tissue. Thus, the methods described herein are useful for improving the structure and / or function of a subject's joint tissue. Without being bound by the following theory, an increase in 15-PGDH levels within joint tissue presenting at least one marker of dysfunction and / or degeneration results in degradation of PGE2 and / or PGD2 within these tissues, and thus, decreases the levels of PGE2 and / or PGD2 and the levels of signaling of PGE2 and / or PGD2, which is thought to have a detrimental effect on joint tissue function. Inhibiting 15-PGDH within joint tissue can result in the recovery or increase of PGE2 and / or PGD2 levels within these tissues and improvement of the structure and / or function of the joint tissue.
[0017] The data described in this disclosure provide preclinical evidence in three different lines of approaches: (a) in aged mice, systemic 15-PGDH inhibition by treatment with a small molecule inhibitor regenerates cartilage; (b) in adult mice, local 15-PGDH inhibition in the knee by intra-articular small molecule inhibitor treatment attenuates OA; and (c) 15-PGDH inhibition in cartilage explants from OA patients induces a regenerative response. Thus, the methods provided herein for inhibiting 15-PGDH activity within a tissue and / or reducing 15-PGDH levels can potentially improve the structure and / or function of a subject's joint tissue, delay or reverse joint injury (e.g., in OA), thereby improving the quality of life and / or outcome of a subject patient having joint tissue that exhibits dysfunction and / or degeneration as a result of aging, injury, disease, disorder, or condition.
[0018] 2. Summary The implementation of the methods disclosed herein uses techniques commonly used in the field of molecular biology. Basic textbooks that disclose the general methods of use described herein include Sambrook and Russell, Molecular Cloning, A Laboratory Manual (3rd ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994).
[0019] In the case of nucleic acids, size is indicated in either kilobases (kb), base pairs (bp), or nucleotides (nt). The size of single-stranded DNA and / or single-stranded RNA can be indicated in nucleotides. These are estimated values obtained from agarose gel electrophoresis or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. In the case of proteins, size is indicated in kilodaltons (kDa) or the number of amino acid residues. Protein size is estimated from gel electrophoresis, from sequenced proteins, from the derived amino acid sequence, or from published protein sequences.
[0020] Oligonucleotides not commercially available can be chemically synthesized using an automated synthesizer as described in Van Devanter et al., Nucleic Acids Res. 12:6159-6168 (1984), following the solid-phase phosphoramidite triester method first described by Beaucage and Caruthers, Tetrahedron Lett. 22:1859-1862 (1981). Purification of oligonucleotides is carried out using any strategy recognized in the art, such as natural acrylamide gel electrophoresis or anion-exchange high-performance liquid chromatography (HPLC) as described in Pearson and Reanier, J. Chrom. 255:137-149 (1983).
[0021] 3. Definition As used herein, the following terms have their meanings unless otherwise specified.
[0022] As used herein, the terms “a,” “an,” and “the” include not only situations having one member but also situations having multiple members. For example, the singular forms “a,” “an,” and “the” include multiple references unless the context clearly indicates otherwise. Thus, for example, a reference to “cell” includes multiple such cells, and a reference to “active substance” includes one or more active substances known to those skilled in the art, and so on.
[0023] As used herein, the terms “about” and “approximately” generally mean an acceptable degree of error in the measured quantity, taking into account the nature or precision of the measurement. Typically, an exemplary degree of error is within 20 percent (%) of a given value or range of values, preferably within 10 percent, and more preferably within 5 percent. Any reference to “about X” means at least the values X, 0.8X, 0.81X, 0.82X, 0.83X, 0.84X, 0.85X, 0.86X, 0.87X, 0.88X, 0.89X, 0.9X, 0.91X, 0.92X, 0.93X, 0.94X, 0.95X, 0.96X, 0.97X, 0.98X, Specifically, this refers to 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.11X, 1.12X, 1.13X, 1.14X, 1.15X, 1.16X, 1.17X, 1.18X, 1.19X, and 1.2X. Thus, "about X" is intended to teach and provide a description that supports a claim limitation such as "0.98X".
[0024] The terms “prostaglandin E2,” “PGE2,” and “dinoprostone” refer to prostaglandins that can be synthesized from arachidonic acid via the cyclooxygenase (COX) enzyme and terminal prostaglandin E synthase (PGES). PGE2 plays some role in many biological functions, including vasodilation, inflammation, and regulation of the sleep / wake cycle. Structural and functional information on PGE2 can be found, for example, in the entry for “dinoprostone” at PubChem:pubchem.ncbi.nlm.nih.gov / compound / Dinoprostone, the contents of which are incorporated herein by reference in their entirety.
[0025] The term “prostaglandin D2” or “PGD2” refers to a prostaglandin that can be synthesized from arachidonic acid via the cyclooxygenase (COX) enzyme and PGD2 synthase (PTDS). PGD2 is a structural isomer of PGE2, where the 9-keto and 11-hydroxyl groups on PGE2 are reversed. PGD2 plays some role in many biological functions, including vasoconstriction, inflammation, regulation of body temperature during sleep, chemotaxis, and male sexual development. Structural and functional information on PGD2 can be found, for example, in the entry for “prostaglandin D2” at PubChem:pubchem.ncbi.nlm.nih.gov / compound / 448457, the contents of which are incorporated herein by reference in their entirety.
[0026] 15-PGDH (15-hydroxyprostaglandin dehydrogenase) is an enzyme involved in the inactivation of several active prostaglandins, for example, by catalyzing the oxidation of PGE2 to 15-keto-prostaglandin E2 (15-keto-PGE2) or the oxidation of PGD2 to 15-keto-prostaglandin D2 (15-keto-PGD2). The human enzyme is encoded by the HPGD gene (gene ID: 3248). This enzyme is a member of the short-chain nonmetallic enzyme alcohol dehydrogenase protein family. In humans, for example, multiple isoforms of this enzyme exist, and any of them can be targeted using this method. For example, any of human isoforms 1-6 (e.g., GenBank accession numbers NP_000851.2, NP_001139288.1, NP_001243236.1, NP_001243234.1, NP_001243235.1, NP_001350503.1, NP_001243230.1) can be targeted, and GenBank accession numbers NP_000851.2, NP_001 The amino acid sequences 139288.1, NP_001243236.1, NP_001243234.1, NP_001243235.1, NP_001350503.1, and NP_001243230.1, or any isoform having 50%, 60%, 70%, 80%, 85%, 90%, 95%, or more identity to any other 15-PGDH enzyme amino acid sequence, can be targeted.
[0027] "15-PGDH inhibitor" refers to any agent that can inhibit, reduce, decrease, attenuate, eliminate, delay, and / or counteract any aspect of the expression, stability, and / or activity of 15-PGDH in any way. A 15-PGDH inhibitor can, for example, reduce the expression of a gene encoding 15-PGDH, such as the human HPGD gene, or any aspect of its transcription, RNA processing, RNA stability, or translation, for example, in the absence of the inhibitor, in vitro or in vivo, compared to a control, by, for example, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. Similarly, 15-PGDH inhibitors can reduce the activity of the 15-PGDH enzyme, for example, its enzymatic activity, by, for example, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more compared to a control, in vitro or in vivo, in the absence of the inhibitor. Furthermore, 15-PGDH inhibitors can, for example, reduce the stability of the 15-PGDH enzyme in vitro or in vivo, in the absence of the inhibitor, compared to a control, by, for example, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more."15-PGDH inhibitors," also referred to herein as "15-PGDH activators" or "15-PGDH compounds," may be any molecule, whether natural or synthetic, e.g., peptides, proteins, oligopeptides (e.g., about 5 to about 25 amino acid lengths, e.g., about 5, about 10, about 15, about 20, or about 25 amino acid lengths), small molecules (e.g., organic molecules having a molecular weight of less than about 2500 daltons, e.g., less than about 2000 daltons, less than about 1000 daltons, or less than about 500 daltons), antibodies, nanobodies, polysaccharides, lipids, fatty acids, inhibitory RNA (e.g., siRNA, shRNA, microRNA), modified RNA, polynucleotides, oligonucleotides, e.g., antisense oligonucleotides, aptamers, affimers, drug compounds, or other compounds.
[0028] The terms “expression” and “expressed” refer to the production of transcripts and / or translation products, e.g., nucleic acid sequences encoding a protein (e.g., 15-PGDH). In some embodiments, the terms refer to the production of transcripts and / or translation products encoded by a gene (e.g., the human HPGD gene) or a portion thereof. The expression level of a DNA molecule within a cell may be assessed based on either the amount of corresponding mRNA present in the cell or the amount of protein encoded by that DNA produced by the cell.
[0029] The term “antibody” refers to a polypeptide encoded by an immunoglobulin gene or a functional fragment thereof that specifically binds to and recognizes an antigen. Recognized immunoglobulin genes include kappa, lambda, alpha, gamma, delta, epsilon, and muon constant region genes, as well as numerous immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, muon, alpha, delta, or epsilon, which define the immunoglobulin classes IgG, IgM, IgA, IgD, and IgE, respectively. The term includes antibody fragments having the same antigen specificity, and their fusion products.
[0030] Exemplary immunoglobulin (antibody) structural units include tetramers. Each tetramer consists of two identical pairs of polypeptide chains, each pair having one "light" chain (approximately 25 kDa) and one "heavy" chain (approximately 50-70 kDa). The N-terminus of each chain defines a variable region of approximately 100-110 amino acids or more, primarily responsible for antigen recognition. Hence the term "variable heavy chain," "V." H "VH" or "V" refers to the variable region of the immunoglobulin heavy chain, including Fv, scFv, dsFv, or Fab, whereas the term "variable light chain" or "V" refers to the variable region of the immunoglobulin heavy chain. L "VL" refers to the variable region of an immunoglobulin light chain, including Fv, scFv, dsFv, or Fab. Equivalent molecules include antigen-binding proteins with desired antigen specificity, obtained, for example, by modifying antibody fragments or by selection from a phage display library.
[0031] The terms “antigen-binding moiety” and “antigen-binding fragment” are used without distinction herein and refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., 15-PGDH protein). Examples of antibody-binding fragments include, but are not limited to, Fab fragments (monovalent fragments consisting of VL, VH, CL, and CH1 domains), F(ab')2 fragments (bivalent fragments containing two Fab fragments linked by disulfide crosslinks at a hinge region), single-chain Fv (scFv), disulfide-linked Fv (dsFv), complementarity-determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), nanobodies, and any combination thereof, or any other functional parts of an immunoglobulin peptide that can bind to a target antigen (see, for example, Fundamental Immunology (Paul ed., 4th ed. 2001)).
[0032] The phrase "specifically binds" refers to a molecule (e.g., a 15-PGDH inhibitor, e.g., a small molecule or antibody) that binds to the target in a sample with greater affinity, binding activity, ease, and / or for a longer period than a non-target compound. In some embodiments, a molecule that specifically binds to a target (e.g., 15-PGDH) binds to the target with at least twice the affinity of a non-target compound, e.g., at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 20 times, at least 25 times, at least 50 times, or more. For example, in some embodiments, a molecule that specifically binds to 15-PGDH typically binds to 15-PGDH with at least twice the affinity of a non-15-PGDH target.
[0033] In the context of compounds, the term “derivative” includes, without limitation, amide, ether, ester, amino, carboxyl, acetyl, and / or alcohol derivatives of a given compound.
[0034] The term “treating” or “treatment” means any one of the following: improving one or more symptoms of a disease, disorder, or condition; preventing the onset of such symptoms before they occur; slowing or completely preventing the progression of a disease, disorder, or condition (which may be evident by lengthening the time between recurrent episodes, slowing the worsening of symptoms, or preventing the worsening of symptoms); enhancing the onset of remission; slowing the progression of a disease, disorder, or condition—the irreversible damage caused in the chronic phase (both primary and secondary phases); delaying the onset of the said progression phase; or any combination thereof.
[0035] The terms “administer,” “administering,” or “administration” refer to methods that may be used to enable the delivery of an active substance or composition, such as the compounds described herein, to a desired site of biological action. These methods include, but are not limited to, parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial, intravascular, intracardiac, intrathecal, intranasal, intradermal, intravitreous, etc.), transmucosal injection, oral administration, administration as a suppository, and topical administration. In some cases, administration is systemic administration (e.g., administration into the circulatory system so that multiple tissues and / or organs are treated or affected). In some cases, administration is topical administration (e.g., directly into a joint tissue or organ so that joint tissue and / or organs are treated or affected). Those skilled in the art will know of additional methods for administering therapeutically effective doses of the compounds described herein.
[0036] The term “therapeutic dose” or “effective amount” refers to the amount of a compound (e.g., a 15-PGDH inhibitor) sufficient to produce a beneficial or desired clinical effect. The therapeutic dose may be based on individual factors for each patient, including, but are not limited to, the patient’s age, size, type or severity of disease, disorder or condition, stage of disease, disorder or condition, route of administration, type or degree of replacement therapy used, and / or ongoing disease process, and / or type of treatment desired (e.g., conventional treatment versus aggressive treatment). The therapeutic dose of any compound or composition described herein (e.g., a 15-PGDH inhibitor) can be initially estimated from cell cultures and animal models. For example, an IC determined by cell culture methods... 50 The value can serve as a starting point in the animal model, but the IC determined in the animal model 50 The value can be used to find the therapeutically effective dose in humans.
[0037] As used herein, the term “pharmaceutical composition” means a composition comprising a compound described herein (e.g., a 15-PGDH inhibitor) and one or more pharmaceutically acceptable carriers and / or pharmaceutically acceptable excipients.
[0038] As used herein, the term “pharmaceutically acceptable carrier” means a carrier or diluent that does not cause significant irritation to an organism and does not impair the biological activity and properties of the administered compound.
[0039] The terms “subject,” “individual,” and “patient” are used herein without distinction to refer to vertebrates, preferably mammals, and more preferably humans. Mammals include, but are not limited to, mice, rats, apes, humans, livestock or animals intended for human consumption, such as pigs, cattle, and sheep, as well as sporting animals and pets. Subject also includes vertebrates such as fish and poultry.
[0040] In the context of compound administration, the term "acute regimen" refers to a transient or short-term application of a compound to a subject, e.g., a human subject, or repeated application of a compound to a subject, e.g., a human subject, with a desired period of time (e.g., one day) between applications. In some embodiments, an acute regimen includes acute exposure of a compound to a subject over a course of treatment or over a long period of time (e.g., a single dose). In other embodiments, an acute regimen includes intermittent exposure of a compound to a subject (e.g., repeated administration) with a desired period of time between each exposure.
[0041] The term “chronic regimen,” in the context of compound administration, refers to the repeated chronic application of a compound to a subject, such as a human subject, over a long period of time, such that the amount or level of the compound remains substantially constant over a selected period. In some embodiments, a chronic regimen includes continuous exposure of a compound to a subject over a long period of time.
[0042] An "expression cassette" is a recombinant or synthetically produced nucleic acid construct that has a set of specific nucleic acid elements that enable the transcription of a particular polynucleotide sequence within a host cell. An expression cassette may be part of a plasmid, viral genome, or nucleic acid fragment. Typically, an expression cassette contains a polynucleotide that is transcribed and operably ligated to a promoter. The promoter may be a heterologous promoter. In the context of a promoter operably ligated to a polynucleotide, a "heterologous promoter" refers to a promoter that is not operably ligated to the same polynucleotide as found in a naturally occurring product (e.g., a wild-type organism).
[0043] The terms “nucleic acid” or “polynucleotide” refer to single-stranded or double-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof. Unless specifically limited, the terms encompass nucleic acids including known analogues of native nucleotides that have similar binding properties to a reference nucleic acid and are metabolized in a similar manner to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence implicitly includes its conservedly modified variants (e.g., degenerate codon substitutions), alleles, orthologues, SNPs, and complementary sequences, as well as explicitly indicated sequences. In certain embodiments, modified RNA molecules are used, for example, mRNA with specific chemical modifications that enable increased stability and / or translation when introduced into cells, as described in further detail below. For example, as described in Dar et al., Scientific Reports 6: article no. 20031 (2016) and presented in the database accessible at crdd.osdd.net / servers / sirnamod / , it is understood that any RNA used in this method, including nucleic acid inhibitors such as siRNA or shRNA, can be used with chemical modifications to enhance stability and / or potency, for example.
[0044] The terms “polypeptide,” “peptide,” and “protein” are used herein without distinction to refer to polymers of amino acid residues. All three terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of corresponding natural amino acids, as well as to natural and non-natural amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins, where the amino acid residues are linked by covalent peptide bonds.
[0045] As used herein, the terms “identical” or percentage “identity” refer to two or more sequences or a specified subsequence that are identical when describing two or more polynucleotide or amino acid sequences. Two sequences that are “substantially identical” have at least about 60% identity, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity when measured using a sequence comparison algorithm or by manual alignment and visual inspection where no specific region is specified. With respect to polynucleotide sequences, this definition also refers to the complement of a test sequence. With respect to the amino acid sequence, identity may, in some cases, exist over a region of at least about 50 amino acids or at least about 50 nucleotides in length, or more preferably over a region of 75 to 100 amino acids or 75 to 100 nucleotides in length.
[0046] In sequence comparison, typically one sequence acts as a reference sequence, and the test sequence is compared against the reference sequence. When using a sequence comparison algorithm, the test sequence and reference sequence are input into a computer, subsequence coordinates are specified as needed, and sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the percentage sequence identity of the test sequence relative to the reference sequence based on the program parameters. For nucleic acid and protein sequence comparison, the BLAST 2.0 algorithm and default parameters are used.
[0047] 4. Methods to improve the structure and / or function of joints In one aspect, a method for improving the structure and / or function of a joint tissue of a subject is provided herein, comprising the step of administering to a subject an amount of a 15-PGDH inhibitor effective in inhibiting the 15-PGDH activity of the subject and / or reducing 15-PGDH levels, thereby improving the structure and / or function of the joint tissue of the subject. The administration of the 15-PGDH inhibitor may be systemic or local and may enhance any of several aspects of the joint tissue, including a reduction in pain and / or pain-related behaviors in the subject; an enhancement of function, physiological activity, endurance, or ability in any assay for assessing tissue function; or an improvement in any other measure of the function or health of the joint tissue of the subject (e.g., as described herein).
[0048] In some embodiments, joint tissues include cartilage, synovial membrane, bone, bone marrow, ligaments, tendons, bursae, menisci, and combinations thereof. In some embodiments, joint tissues originate from any joint of the subject (e.g., knee, ankle, hip, hand, wrist, elbow, spine, neck, shoulder, etc.).
[0049] In some embodiments, the levels of PGE2 and / or PGD2 present in the joint tissue may increase compared to the levels present in the joint tissue before treatment (e.g., with a 15-PGDH inhibitor) or compared to the levels present in healthy joint tissue from the same subject (e.g., after treatment with a 15-PGDH inhibitor according to the method provided herein). The levels of PGE2 and / or PGD2 in the joint tissue may increase by at least about 10% (e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or more) compared to the levels present in the joint tissue before treatment (e.g., with a 15-PGDH inhibitor) or compared to the levels present in healthy joint tissue from the same subject (e.g., by any method disclosed herein). In some embodiments, the levels of PGE2 and / or PGD2 in the joint tissue increase by at least 10%. In some embodiments, the levels of PGE2 and / or PGD2 in the joint tissue increase by at least 50%. In some embodiments, the joint tissue in question presents at least one marker of dysfunction and / or degeneration, and the levels of PGE2 and / or PGD2 present in the joint tissue can increase to levels substantially similar to those present in joint tissue in question that does not present at least one marker of dysfunction and / or degeneration (for example, after treatment with a 15-PGDH inhibitor according to the method provided herein). PGE2 and / or PGD2 levels in joint tissue can increase to levels within approximately 10% to approximately 200% of the levels present in the joint tissue of interest that does not present at least one marker of dysfunction and / or degeneration (e.g., approximately 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%, or more) (e.g., by any method disclosed herein).In some embodiments, PGE2 and / or PGD2 levels in the joint tissue increase to within 50% of the levels present in the joint tissue in question that do not present with at least one marker of dysfunction and / or degeneration.
[0050] In some embodiments, levels of PGE2 and / or PGD2 metabolites present in joint tissue may decrease compared to levels present in joint tissue before treatment (e.g., with a 15-PGDH inhibitor) or compared to levels present in healthy joint tissue from the same subject (e.g., after treatment with a 15-PGDH inhibitor according to the methods provided herein). Levels of PGE2 and / or PGD2 metabolites present in joint tissue may decrease by at least about 10% (e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or more) compared to levels present in joint tissue before treatment (e.g., with a 15-PGDH inhibitor) or compared to levels present in healthy joint tissue from the same subject (e.g., by any method disclosed herein). In some embodiments, the joint tissue in question presents at least one marker of dysfunction and / or degeneration, and the levels of PGE2 and / or PGD2 metabolites present in the joint tissue can be reduced to substantially the same level as those present in the joint tissue in question that does not present at least one marker of dysfunction and / or degeneration (e.g., after treatment with a 15-PGDH inhibitor according to the methods provided herein). The levels of PGE2 and / or PGD2 metabolites in the joint tissue can be reduced to about 50% or less of the levels present in the joint tissue in question that does not present at least one marker of dysfunction and / or degeneration (e.g., within about 40%, within about 35%, within about 30%, within about 25%, within about 20%, within about 15%, within about 10%, within about 5%, or within about 1%) (e.g., by any method disclosed herein). The PGE2 and / or PGD2 metabolites may be 15-ketoPGE2, 13,14-dihydro-15-ketoPGE2, or both.
[0051] In some embodiments, the methods provided herein (e.g., treatment with a 15-PGDH inhibitor) result in improvements in the structure and / or function of the joint tissue in question, as demonstrated by a reduction in at least one marker of joint tissue dysfunction and / or degeneration. Markers of joint tissue dysfunction and / or degeneration include, but are not limited to, decreased cartilage proteoglycan (GAG) staining, decreased cartilage thickness, increased fibrosis, decreased smoothness of the cartilage surface, decreased bone tissue density, increased OARSI score (e.g., see Glasson, et al., 2010, “The OARSI histopathology initiative—recommendations for histological assessments of osteoarthritis in the mouse,” Osteoarthr. Cartil. 18(Suppl.3):S17-23), and combinations thereof.Markers of joint tissue dysfunction and / or degeneration include, but are not limited to, decreased levels of sulfated glycosaminoglycans (sGAGs), decreased cell proliferation (e.g., as measured by a decrease in cells expressing the cell cycle marker Ki67), increased pain and / or pain-related behavior in the subject, increased expression of Indian Hedgehog (Ihh) protein, increased expression of catabolic genes (e.g., matrix metalloproteinase (MMP)-13, MMP-3, MMP-1, aggrecanase, disintegrin and metalloproteinase 4 with a thrombospondin motif (ADAMTS4), ADAMTS5, cathepsin, etc.), decreased expression of anabolic chondrocyte genes (e.g., Sox9, collagen II, Acan, etc.), decreased expression of genes involved in mitochondrial function and metabolism (e.g., Cox5a, Ndufa9), and mitochondrial dysfunction. This may also include increased expression of genes involved in osteoarthritis (e.g., Htra1, Dcn), decreased mitochondrial biosynthesis, decreased mitochondrial levels (e.g., mitochondria / cell), increased levels of type X collagen, increased chondrocyte size, increased chondrocyte sphericity, increased levels of cytokines and / or chemokines (e.g., IL1, IL6, IL15, oncostatin M, tumor necrosis factor, CCL7, CXCL10, CCL4, VEGF, IL27, IL2, GMCSF, CCL5, etc.), increased levels of inflammatory mediators (e.g., nitric oxide, reactive oxygen species, complement activation, etc.), increased levels of cell-derived products and / or matrix-derived products (e.g., alarmins, e.g., S100, fibronectin fragments, hyaluronic acid fragments, collagen fragments, proteoglycan fragments, high-mobility box, etc.), as well as combinations thereof.In some embodiments, markers of joint tissue dysfunction and / or degeneration may include other markers known to those skilled in the art (for example, as described in Wei, et al., 2012, “Activation of Indian hedgehog promotes chondrocyte hypertrophy and upregulation of MMP-13 in human osteoarthritic cartilage,” Osteoarthr.Cartil.20:755-763 and / or Martel-Pelletier, et al., 2016, “Osteoarthritis,” Nature Reviews 2:1-18, respectively, which are incorporated herein by reference in their entirety).
[0052] Therefore, a decrease in markers of joint tissue dysfunction and / or degeneration may, in some embodiments, include increased GAG staining, increased cartilage thickness, decreased fibrosis, increased smoothness of the cartilage surface, increased bone tissue density, decreased OARSI score, or a combination thereof. In some embodiments, a decrease in markers of joint tissue dysfunction and / or degeneration may include increased sGAG levels, increased cell proliferation (e.g., measured by an increase in cells expressing Ki67), decreased pain and / or pain-related behavior in the subject, decreased Ihh protein expression, decreased expression of catabolic genes (e.g., MMP-13, MMP-3, MMP-1, aggrecanase, ADAMTS4, ADAMTS5, cathepsin, etc.), increased expression of anabolic chondrocyte genes (e.g., Sox9, collagen II, Acan, etc.), increased expression of genes involved in mitochondrial function and metabolism (e.g., Cox5a, Ndufa9), and increased expression of genes involved in mitochondrial dysfunction and / or osteoarthritis (e.g., Htra1, Dcn). Possible effects include a decrease in current levels, an increase in mitochondrial biosynthesis, an increase in mitochondrial levels, a decrease in type X collagen levels, a decrease in chondrocyte size, a decrease in chondrocyte sphericity, a decrease in cytokine and / or chemokine levels (e.g., IL1, IL6, IL15, oncostatin M, tumor necrosis factor, CCL7, CXCL10, CCL4, VEGF, IL27, IL2, GMCSF, CCL5, etc.), a decrease in inflammatory mediator levels (e.g., nitric oxide, reactive oxygen species, complement activation, etc.), a decrease in cell-derived products and / or matrix-derived products (e.g., alarmin, e.g., S100, fibronectin fragments, hyaluronic acid fragments, collagen fragments, proteoglycan fragments, high-mobility box, etc.), and combinations thereof.
[0053] In some embodiments, the reduction of markers of joint tissue dysfunction and / or degeneration may include an increase or enhancement of joint tissue function as measured by mechanical methods (e.g., mechanical testing of bulk tissue specimens, microbeam mechanical testing, microindentation, or nanoindentation); imaging methods (e.g., computed tomography (CT), magnetic resonance imaging (MRI), nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (FTIR), Raman imaging, or scanning electron microscopy); chemical or physical methods (gravimetric or chemical analysis of collagen crosslinks); densitometry; or a combination thereof. The structure and / or function of the joint tissue may be improved by at least about 10% (e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or more) compared to the joint tissue before treatment (e.g., with a 15-PGDH inhibitor) or compared to the levels present in healthy joint tissue from the same subject (e.g., by any method disclosed herein). In some embodiments, the joint tissue in question may present at least one marker of dysfunction and / or degeneration, and the structure and / or function of the joint tissue may be improved to a level substantially similar to that present in the joint tissue in question that does not present at least one marker of dysfunction and / or degeneration (e.g., after treatment with a 15-PGDH inhibitor according to the method provided herein). The structure and / or function of the joint tissue may be improved to a level within about 10% to about 200% of the level present in the joint tissue in question that does not present at least one marker of dysfunction and / or degeneration (e.g., about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, or about 200% or more) (e.g., by any method disclosed herein).In some embodiments, the structure and / or function of the joint tissue is improved to a level within approximately 50% of the level present in the joint tissue in question that does not present at least one marker of dysfunction and / or degeneration (e.g., by any method disclosed herein).
[0054] In some aspects, improvements in joint tissue function and activity are demonstrated by improvements in pain, disease activity, or physical disability of approximately 50%, 60%, 70%, 80%, 90%, 95%, 100%, or more. In some aspects, improvements in joint tissue function and activity are demonstrated by improvements in ACR (American College of Rheumatology) criteria, including the ACR20, ACR50, or ACR70 criteria. The ACR criteria are used to assess and establish improvements in the number of tenderness or joint swellings, along with improvements in three of the following five parameters: 1) Acute-phase reactant - the amount of inflammation in the joint, measured by C-reactive protein or sedimentation rate; 2) Patient assessment - progress to joint treatment and patient response; 3) Healthcare provider assessment - assessment of progress to treatment and response by the healthcare provider; 4) Pain - the patient's level of joint pain; and 5) Physical disability / functional questionnaire - the level of interference of joint disease in daily activities.
[0055] In some embodiments, improvements in joint tissue function and activity are demonstrated by a reduction in pain and / or pain-related behaviors. In some embodiments, pain in subjects (e.g., OA-related pain) is assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a set of standardized questionnaires used by healthcare professionals as patient-reported outcomes (PROs) to assess joint pain, stiffness, and physical function in subjects (see, e.g., Bellamy, 1989, Seminars in Arthritis and Rheumatism, 18(4)supp.2:14-17; Peat et al., 2001, Ann. Rheum. Dis. 60:91e7; and Neogi, 2013, Osteoarthritis and Cartilage 21:1145-1153). In some aspects, pain and / or pain-related behaviors can be assessed by gait analysis (e.g., using a catwalk video-based system) and / or by testing for mechanical allodynia (e.g., using the von Frey filament assay) (e.g., in small animals) (see, e.g., Malfait et al., 2013, Osteoarthritis and Cartilage 21:1316-1326).
[0056] Techniques for evaluating the structure and / or function of joint tissues are known to those skilled in the art. For example, histological examination of cartilage proteoglycan (GAG) staining with safranin O can reveal dysfunction and / or degeneration through a decrease in GAG staining. Other examples, without limitation, include examination of the level of fibrosis, examination of cartilage thickness, examination of the level of smoothness of the cartilage surface, examination of bone tissue density, OARSI scoring, histological examination of joint tissue for the presence of additional markers (e.g., sGAG, type X collagen, chondrocyte size, chondrocyte sphericity, cytokines and / or chemokines, inflammatory mediators, and / or cell-derived and / or matrix-derived products), measurement of cell proliferation (e.g., by measurement of cell proliferation markers such as Ki67), quantification of the expression of the above marker genes (e.g., at the protein level by techniques such as Western blotting, immunofluorescence, flow cytometry or mass spectrometry; or at the mRNA level by techniques such as quantitative reverse transcriptase PCR or RNA sequencing), or combinations thereof. In some embodiments, decreased expression of anabolic chondrocyte genes (e.g., Sox9, collagen II, or Acan) indicates joint dysfunction and / or degeneration. In some embodiments, increased expression of catabolic genes (e.g., MMP-13 or MMP-3) indicates joint dysfunction and / or degeneration. In some embodiments, decreased expression of genes involved in mitochondrial function and metabolism (e.g., Cox5a, Ndufa9) indicates joint dysfunction and / or degeneration. In some embodiments, increased expression of genes involved in mitochondrial dysfunction and / or osteoarthritis (e.g., Htra1, Dcn) indicates joint dysfunction and / or degeneration. In some embodiments, increased pain (e.g., assessed according to any of the methods described herein) indicates joint dysfunction and / or degeneration. Joint tissue function can also be assessed through medical techniques including macroscopic examination for abnormalities, observation of joint movement, joint palpation, and combinations thereof.
[0057] In some embodiments, the treatment (e.g., using a 15-PGDH inhibitor according to the method provided herein) results in a reduction, decrease, attenuation, or inhibition of joint tissue dysfunction. Joint tissue dysfunction includes, but is not limited to, any feature that impairs the normal function of the joint, including joint pain, reduced range of motion, pain, and combinations thereof. The level of joint tissue dysfunction may be measured using any of the techniques described herein or any other method known to those skilled in the art. In some embodiments, efficacy may be measured using standard clinical measures of joint tissue function and activity (e.g., Disability Index of the Health Assessment Questionnaire (HAQ); and a physician's overall assessment of disease activity), including improvement in pain, disease activity, and physical disability. In some embodiments, efficacy may be measured using ACR (American College of Rheumatology) criteria, including ACR20, ACR50, or ACR80. See, for example, van de Putte et al., Ann. Rheum. Dis 62:1168-1177 (2003). In some embodiments, the treatment (e.g., using a 15-PGDH inhibitor according to the method provided herein) results in increased expression of anabolic chondrocyte genes (e.g., Sox9, collagen II, or Acan). In some embodiments, the treatment (e.g., using a 15-PGDH inhibitor according to the method provided herein) results in decreased expression of catabolic genes (e.g., MMP-13 or MMP-3). In some embodiments, the treatment (e.g., using a 15-PGDH inhibitor according to the method provided herein) results in increased hematopoietic function and / or rejuvenation of the hematopoietic stem cell (HSC) niche.
[0058] In some embodiments, the treatment (e.g., using a 15-PGDH inhibitor according to the method provided herein) results in a reduction, decrease, attenuation, cessation, or inhibition of joint tissue degeneration and / or pain. Joint tissue degeneration includes, but is not limited to, loss, weakening, deterioration, or functional impairment of any tissue involved in joint function, including cartilage, synovial membrane, bone, bone marrow, ligaments, tendons, bursae, menisci, and combinations thereof. In some embodiments, the joint tissue originates from any joint in question (e.g., knee, ankle, hip, hand, wrist, elbow, spine, neck, shoulder, etc.). The level of joint tissue degeneration can be measured using any of the techniques described herein or any other method known to those skilled in the art.
[0059] In some embodiments, a 15-PGDH inhibitor reduces joint tissue dysfunction and / or degeneration by at least about 10% (e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or more) compared to cells and / or tissue before treatment (e.g., with the 15-PGDH inhibitor) or compared to levels present in healthy joint cells and / or tissue from the same subject. In some embodiments, the subject presents at least one marker of dysfunction and / or degeneration, and the 15-PGDH inhibitor reduces at least one marker of joint tissue dysfunction and / or degeneration to a level substantially similar to that present in joint tissue of the subject that does not present at least one marker of dysfunction and / or degeneration (e.g., after treatment with the 15-PGDH inhibitor according to the method provided herein). At least one marker of dysfunction and / or degeneration of joint tissue can be reduced to a level of about 10% to about 200% or less (e.g., within about 40%, within about 35%, within about 30%, within about 25%, within about 20%, within about 15%, within about 10%, within about 5%, or within about 1%) that is present in the joint tissue of the subject that does not show at least one marker of dysfunction and / or degeneration (e.g., by any method disclosed herein).
[0060] This disclosure also provides methods for treating diseases, disorders, or conditions affecting joint tissue, such as any type of arthritis, osteoarthritis, osteoporosis, rheumatoid arthritis, juvenile idiopathic arthritis, gout, systemic lupus erythematosus, seronegative spondyloarthritis, degenerative disc disease, congenital cartilage disorders, bone disorders, and combinations thereof. In some embodiments, the disease, disorder, or condition is rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, connective tissue disease psoriasis, polyarthritis, or osteoarthritis. In some embodiments, the method comprises administering a therapeutically effective amount of a pharmaceutical composition containing a 15-PGDH inhibitor to a subject having a disease, disorder, or condition affecting joint tissue (e.g., as described herein). In some embodiments, the subjects have rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, connective tissue disease psoriasis, polyarthritis, or osteoarthritis.
[0061] This disclosure also provides a method for measuring 15-PGDH levels in joint tissue of a subject having at least one marker of dysfunction and / or degeneration. Such a method is useful, for example, for the use of 15-PGDH as a biomarker of joint tissue dysfunction and / or degeneration, for example, an increase in the level of 15-PGDH level or activity, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more compared to a control level in a control subject without joint tissue dysfunction and / or degeneration, or compared to a healthy joint in the subject, indicates joint tissue dysfunction and / or degeneration. In such a method, 15-PGDH can be evaluated by any of several methods, for example, by detecting the level of a transcript encoding the 15-PGDH protein, by detecting the level of a 15-PGDH polypeptide, or by detecting 15-PGDH enzyme activity.
[0062] In certain embodiments, inhibition of 15-PGDH in a subject results in an increase in PGE2 and / or PGD2 in the joint tissue of the subject, e.g., an elevation, increase, or recovery of PGE2 and / or PGD2 levels, and a decrease in PGE2 and / or PGD2 metabolites such as 15-keto-PGE2, 13,14-dihydro-15-keto-PGE2 (PGEM), 15-keto-PGD2, and 13,14-dihydro-15-keto-PGD2. In some embodiments, inhibition also results in an increase in signaling via PGE2 receptors in joint tissue, e.g., EP1, EP2, EP3, and / or EP4 (also known as Ptger1, Ptger2, Ptger3, and Ptger4). In some embodiments, inhibition also results in an increase in signaling via PGD2 receptors, e.g., DP1 and / or DP2 (also known as PTGDR1, PTGDR2 / CRTH2).
[0063] In certain embodiments, the benefits described herein of administering a 15-PGDH inhibitor into joint tissue, such as improved joint tissue function, occur independently of any regeneration of the joint tissue in question. In other words, for example, if the joint tissue has been damaged or injured, the joint tissue in question may regenerate, but the effects described herein do not require regeneration and occur even without regeneration. In certain embodiments, the joint tissue is not damaged or injured, has not experienced regeneration, or has not experienced regeneration.
[0064] subject The subjects may be any subject having at least one marker of joint tissue dysfunction and / or degeneration, or at risk of having at least one marker of joint tissue dysfunction and / or degeneration, e.g., humans or other mammals. In some embodiments, the subjects are humans. In some embodiments, the subjects are adults. In some embodiments, the subjects are children. In some embodiments, the subjects are females (e.g., adult women). In some embodiments, the subjects are males (e.g., adult men).
[0065] In some embodiments, the subjects are human, and the method further includes a step in which a human is selected for treatment with a 15-PGDH inhibitor based on the determination that the human has at least one marker of joint tissue dysfunction and / or degeneration, or based on the likelihood or risk of developing at least one marker of joint tissue dysfunction and / or degeneration. In some such embodiments, the human is selected based on his / her age. For example, a human may be selected for treatment based on the age of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 years or older, or on any age at which the human has or may have at least one marker of joint tissue dysfunction and / or degeneration. In some embodiments, the subjects are under 30 years of age. In some embodiments, the subjects are at least 30 years of age. In some embodiments, individuals are selected based on the possibility of at least one marker of joint tissue dysfunction and / or degeneration, and on the presence or potential presence of environmental, lifestyle, or medical factors associated with joint tissue dysfunction and / or degeneration, such as a family history of joint problems, diet, lack of physical activity, sleep deprivation, drug use, smoking, alcohol consumption, exposure to extreme temperatures, stress, excessive weight, or health-related factors, such as infection, disease, disorder, or pathology.
[0066] In some embodiments, subjects are determined to have dysfunction and / or degeneration of joint tissue as determined by any method of evaluating any measure of function, capacity, health, strength, endurance, physiological activity or any other property of joint tissue, e.g., capacity-based assays, image-based assays, physiological assays, molecular assays, cellular assays or functional assays. In some embodiments, subjects are selected for treatment based on an assessment of the structure and / or function of joint tissue. In some embodiments, subjects are selected for treatment based on the detection of elevated levels of 15-PGDH transcript, protein or enzyme activity in joint tissue, or based on the detection of decreased levels of PGE2 and / or PGD2 in joint tissue.
[0067] In some embodiments, the method includes evaluating the health, function, capacity or any other properties of the joint tissue in question after administration of a 15-PGDH inhibitor, or includes an additional step of evaluating the levels of 15-PGDH (e.g., 15-PGDH protein, transcript or activity) and / or PGE2 and / or PGD2 in the joint tissue in question to confirm, for example, the potential effect of prior administration of a 15-PGDH inhibitor to the joint tissue. In some such embodiments, the health, function, capacity, 15-PGDH levels, PGE2 levels, PGD2 levels, or other properties of the joint tissue are detected or examined and compared to the health, function, capacity, 15-PGDH levels, PGE2 levels, PGD2 levels, or other properties of the joint tissue before administration of the 15-PGDH inhibitor, or to control values. A determination that the health, function, or capacity of the joint tissue has improved, that the 15-PGDH levels in the joint tissue have decreased, or that the PGE2 and / or PGD2 levels have increased after administration of the inhibitor, compared to the values obtained before administration of the 15-PGDH inhibitor or to control values, indicates that the 15-PGDH inhibitor had a beneficial effect in the joint tissue in question.
[0068] In some embodiments, subjects are, for example, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 years of age or older. In some embodiments, older subjects present with at least one marker of joint tissue dysfunction and / or degeneration as a result of aging.
[0069] In some embodiments, the subject has endured injuries affecting joint tissue, such as cartilage damage, joint injury, trauma, anterior cruciate ligament (ACL) rupture, meniscus tear, hip labral tear, rotator cuff injury, spondylosis, vertebral fracture, hip fracture, degenerative spondylolisthesis, spondylolisthesis, herniated disc, and combinations thereof. In some embodiments, the joint tissue originates from any joint of the subject (e.g., knee, ankle, hip, hand, wrist, elbow, spine, neck, shoulder, etc.). In some embodiments, the injured subject presents at least one marker of dysfunction and / or degeneration of the joint tissue as a result of the injury.
[0070] In some embodiments, the subject has a disease, disorder, or condition affecting joint tissue, e.g., any type of arthritis, osteoarthritis, osteoporosis, rheumatoid arthritis, juvenile idiopathic arthritis, gout, systemic lupus erythematosus, seronegative spondyloarthropathy, degenerative disc disease, congenital cartilage disorders, bone disorders, and combinations thereof. In some embodiments, the subject has osteoarthritis. In some embodiments, the joint tissue originates from any joint of the subject (e.g., knee, ankle, hip, hand, wrist, elbow, spine, neck, shoulder, etc.). In some embodiments, the subject having a disease, disorder, or condition presents at least one marker of joint tissue dysfunction and / or degeneration as a result of the disease, disorder, or condition.
[0071] This method may be used, without limitation, to treat any joint tissue, or cells within such tissue, including cartilage, synovial membrane, bone, bone marrow, ligaments, tendons, bursae, menisci, and combinations thereof. In some embodiments, the joint tissue may originate from any joint of the subject (e.g., knee, ankle, hip, hand, wrist, elbow, spine, neck, shoulder, etc.).
[0072] 5. Evaluation of 15-PGDH level For example, when using 15-PGDH as a biomarker, or when evaluating the effects of 15-PGDH inhibitors, the level of 15-PGDH in the tissue can be assessed using one of several methods. For instance, the level of 15-PGDH can be assessed by examining the transcription of the gene encoding 15-PGDH (e.g., the Hpgd gene), by examining the level of 15-PGDH protein in the tissue, or by measuring the 15-PGDH enzyme activity in the tissue. Such methods can be performed on the entire tissue or on a subset of cells within the tissue.
[0073] In some embodiments, the method includes the step of measuring 15-PGDH enzyme activity by using standard methods such as incubating a candidate compound in the presence of 15-PGDH enzyme, NAD(+), and PGE2 and / or PGD2 in a suitable reaction buffer and monitoring the production of NADH (see, for example, Zhang et al., (2015) Science 348:1224), or by using one of several available kits such as the Fluorescence Quantitative PicoProbe 15-PGDH Activity Assay Kit (BioVision), or by using one of the methods and / or indicators described in, for example, EP2838533 B1.
[0074] In some embodiments, the method involves detecting the expression of polynucleotides encoding 15-PGDH (e.g., mRNA), which can be analyzed using common techniques such as RT-PCR, real-time RT-PCR, semi-quantitative RT-PCR, quantitative polymerase chain reaction (qPCR), quantitative RT-PCR (qRT-PCR), multiplexed branched DNA (bDNA) assay, microarray hybridization, or sequence analysis (e.g., RNA sequencing ("RNA-Seq")). Methods for quantifying polynucleotide expression are described, for example, in Fassbinder-Orth, Integrative and Comparative Biology, 2014, 54:396-406; Thellin et al., Biotechnology Advances, 2009, 27:323-333; and Zheng et al., Clinical Chemistry, 2006, 52:7 (doi:10 / 1373 / clinchem. 2005. 065078). In some embodiments, real-time PCR, quantitative PCR, or RT-PCR is used to measure the level of polynucleotides (e.g., mRNA) in biological samples. See, for example, Nolan et al., Nat. Protoc, 2006, 1:1559-1582; and Wong et al., BioTechniques, 2005, 39:75-75. In addition, quantitative PCR assays and RT-PCR assays for measuring gene expression are commercially available (e.g., TaqMan® gene expression assay, ThermoFisher Scientific).
[0075] In some embodiments, the method includes a step of detecting the expression or stability of the 15-PGDH protein using, for example, common techniques known to those skilled in the art, such as immunoassays, two-dimensional gel electrophoresis, and quantitative mass spectrometry. Protein quantification techniques are generally described in "Strategies for Protein Quantitation," Principles of Proteomics, 2nd Edition, R. Twyman, ed., Garland Science, 2013. In some embodiments, protein expression or stability is detected by immunoassays, for example, without limitation, enzyme-enzyme-immunoassays (EIAs), such as enzyme amplification immunoassay techniques (EMIT), enzyme-linked immunosorbent assays (ELISAs), IgM antibody capture ELISA (MAC ELISA), and microparticle enzyme-enzyme-immunoassays (MEIA); capillary electrophoresis immunoassays (CEIA); radioimmunoassays (RIA); immunoradiometric assays (IRMA); immunofluorescence (IF); fluorescence-polarized immunoassays (FPIA); and chemiluminescence assays (CL). Such immunoassays can be automated if desired. Immunoassays can also be used in conjunction with laser-induced fluorescence (see, for example, Schmalzing et al., Electrophoresis, 18:2184-93 (1997); Bao, J. Chromatogr. B. Biomed. Sci., 699:463-80 (1997)).
[0076] 6. 15-PGDH as a biomarker In some embodiments, 15-PGDH may be used as a biomarker for joint tissue dysfunction and / or degeneration, or for the presence or possibility of disease, disorder, or pathology affecting joint tissue. For example, detection of elevated levels of 15-PGDH in joint tissue, e.g., the entire tissue, or in specific cells within joint tissue may indicate loss or decline in joint tissue function or health, or the presence or onset of aging, injury, disease, disorder, or pathology, associated with joint tissue dysfunction and / or joint tissue degeneration, aging, injury, disease, or disorder. For example, a detected increase of approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more in 15-PGDH within joint tissue compared to control tissue from subjects without disease, disorder, or pathology affecting joint tissue may indicate joint tissue dysfunction and / or loss or reduction of joint tissue function or health, or the presence or occurrence of aging, injury, disease, disorder, or pathology related to joint tissue degeneration, aging, injury, disease, disorder, or pathology.
[0077] 7. 15-PGDH inhibitors In this method, any active substance may be used that reduces, decreases, counteracts, attenuates, inhibits, blocks, downregulates, or eliminates the expression, stability, or activity of 15-PGDH, such as its enzyme activity, in any way. The inhibitor may be any small molecule compound, peptide, polypeptide, nucleic acid, antibody, e.g., blocking antibody or nanobody, or any other molecule that reduces, decreases, counteracts, attenuates, inhibits, blocks, downregulates, or eliminates the expression, stability, and / or activity of 15-PGDH, such as its enzyme activity.
[0078] In some embodiments, a 15-PGDH inhibitor reduces the activity, stability, or expression of 15-PGDH by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or more, in vivo or in vitro, for example, in the absence of the inhibitor, compared to control levels.
[0079] The effect of inhibitors can be evaluated, for example, by measuring 15-PGDH enzyme activity using standard methods such as incubating candidate compounds in the presence of 15-PGDH enzyme, NAD(+), and PGE2 in a suitable reaction buffer and monitoring NADH production (see, e.g., Zhang et al., (2015) Science 348:1224), or by using one of several available kits such as the Fluorescence Quantitative PicoProbe 15-PGDH Activity Measurement Kit (BioVision), or by using one of the methods and / or indices described, for example, EP2838533 B1.
[0080] The effects of inhibitors can also be assessed by detecting reduced polynucleotide (e.g., mRNA) expression, which can be analyzed using common techniques such as RT-PCR, real-time RT-PCR, semi-quantitative RT-PCR, quantitative polymerase chain reaction (qPCR), quantitative RT-PCR (qRT-PCR), multiple branched DNA (bDNA) assays, microarray hybridization, or sequence analysis (e.g., RNA sequencing ("RNA-Seq")). Methods for quantifying polynucleotide expression are described, for example, in Fassbinder-Orth, Integrative and Comparative Biology, 2014, 54:396-406; Thellin et al., Biotechnology Advances, 2009, 27:323-333; and Zheng et al., Clinical Chemistry, 2006, 52:7 (doi:10 / 1373 / clinchem. 2005. 065078). In some embodiments, real-time PCR, quantitative PCR, or RT-PCR are used to measure the levels of polynucleotides (e.g., mRNA) in biological samples. See, for example, Nolan et al., Nat. Protoc, 2006, 1:1559-1582; Wong et al., BioTechniques, 2005, 39:75-75. Quantitative PCR and RT-PCR assays for measuring gene expression are also commercially available (e.g., TaqMan® gene expression assay, ThermoFisher Scientific).
[0081] In some embodiments, a 15-PGDH inhibitor is considered effective when the expression level of the polynucleotide encoding 15-PGDH is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more, in vitro or in vivo, compared to a reference value, e.g., the value in the absence of the inhibitor. In some embodiments, a 15-PGDH inhibitor is considered effective when the expression level of the polynucleotide encoding 15-PGDH is reduced by at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, or more, compared to a reference value.
[0082] The effects of 15-PGDH inhibitors can also be evaluated by detecting protein expression or stability using common techniques known to those skilled in the art, such as immunoassays, two-dimensional gel electrophoresis, and quantitative mass spectrometry. Protein quantification techniques are generally described in "Strategies for Protein Quantitation," Principles of Proteomics, 2nd Edition, R. Twyman, ed., Garland Science, 2013. In some embodiments, protein expression or stability is detected by immunoassays, for example, without limitation, enzyme-enzyme-immunoassays (EIAs), such as enzyme amplification immunoassay techniques (EMIT), enzyme-linked immunosorbent assays (ELISAs), IgM antibody capture ELISA (MAC ELISA), and microparticle enzyme-enzyme-immunoassays (MEIA); capillary electrophoretic immunoassays (CEIA); radioimmunoassays (RIA); immunoradiometric assays (IRMA); immunofluorescence (IF); fluorescence-polarized immunoassays (FPIA); and chemiluminescence assays (CLs). Such immunoassays can be automated if desired. Immunoassays can also be used in conjunction with laser-induced fluorescence (see, for example, Schmalzing et al., Electrophoresis, 18:2184-93 (1997); Bao, J. Chromatogr. B. Biomed. Sci., 699:463-80 (1997)).
[0083] To determine whether 15-PGDH protein levels decrease in the presence of a 15-PGDH inhibitor, the method includes the step of comparing the level of the protein (e.g., 15-PGDH protein) in the presence of the inhibitor to a reference value, e.g., the level in the absence of the inhibitor. In some embodiments, 15-PGDH protein is decreased in the presence of the inhibitor if the level of 15-PGDH protein decreases by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more compared to the reference value. In some embodiments, 15-PGDH protein is decreased in the presence of the inhibitor if the level of 15-PGDH protein decreases by at least about 1.5 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, or more compared to the reference value.
[0084] small molecule In certain embodiments, 15-PGDH is inhibited by administration of a small molecule inhibitor. Any small molecule inhibitor can be used that reduces the expression, stability, or activity of 15-PGDH, for example, in the absence of the inhibitor, by about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more, compared to a control. In certain embodiments, small molecule inhibitors that can reduce the enzymatic activity of 15-PGDH in vitro or in vivo may be used. Non-limiting examples of small molecule compounds that can be used in this method include the small molecules disclosed in EP2838533 B1, the entire disclosure of which is incorporated herein by reference. Small molecules include, in particular, EP2838533 The small molecules disclosed in Table 2 of B1 may include SW033291, SW033291 isomer B, SW033291 isomer A, SW033292, 413423, 980653, 405320, SW208078, SW208079, SW033290, SW208080, SW208081, SW206976, SW206977, SW206978, SW206979, SW206980, SW206992, SW208064, SW208065, SW208066, SW208067, SW208068, SW208069, SW208070, and combinations, derivatives, isomers, or tautomers thereof. In certain embodiments, the 15-PGDH inhibitor used is SW033291 (2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridine-3-amine; PubChem CID:3337839).
[0085] In some embodiments, the 15-PGDH inhibitor is a thiazolidinedione derivative (e.g., benzylidene thiazolidine-2,4-dione derivative), e.g., (5-(4-(2-(thiophen-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione), 5-(3-chloro-4-phenylethoxybenzylidene)thiazolidine-2,4-dione, 5-(4-(2-cyclohexylethoxy)benzylidene)thiazolidine-2,4-dione, 5-(3-chloro-4-(2-cyclohexylethoxy)benzyl)thiazolidine-2,4-dione, (Z)-N-benzyl-4-((2,4-dioxothiazolidine-5-ylidene)methyl)benzamide, or the entire disclosure thereof is incorporated herein by reference by Choi et al. (2013) Bioorganic & Medicinal Chemistry 21:4477-4484; Wu et al. (2010) Bioorg. Med. Chem. 18(2010)1428-1433; Wu et al. (2011) J. Med. Chem. 54:5260-5264; or any of the compounds disclosed in Yu et al. (2019) Biotechnology and Bioprocess Engineering 24:464-475. In some embodiments, the 15-PGDH inhibitor is a COX inhibitor or chemopreventive agent, such as siglitazone (CID:2750), or any of the compounds disclosed in Cho et al. (2002) Prostaglandins, Leukotrienes and Essential Fatty Acids 67(6):461-465, the entire disclosure of which is incorporated herein by reference.
[0086] In some embodiments, the 15-PGDH inhibitor is a compound containing a benzimidazole group, for example, (1-(4-methoxyphenyl)-1H-benzo[d]imidazole-5-yl)(piperidine-1-yl)methanone (CID:3474778), or a compound containing a triazole group, for example, 3-(2,5-dimethyl-1-(p-tolyl)-1H-pyrrole-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine (CID:71307851), or the entire disclosure of Duveau et al. (2015) (published in Probe Reports from the NIH Molecular Libraries Program [Internet]) as "Discovery of two small molecule inhibitors, ML387 and ML388, of human NAD+-dependent 15-hydroxyprostaglandin The 15-PGDH inhibitor is one of the compounds disclosed in dehydrogenase''. In some embodiments, the 15-PGDH inhibitor is 1-(3-methylphenyl)-1H-benzimidazole-5-yl)(piperidine-1-yl)methanone (CID:4249877), or one of the compounds disclosed in Niesen et al. (2010) PLoS ONE 5(11):e13719, the entire disclosure of which is incorporated herein by reference.In some embodiments, the 15-PGDH inhibitor is 2-((6-bromo-4H-imidazo[4,5-b]pyridine-2-ylthio)methyl)benzonitrile (CID: 3245059), piperidine-1-yl(1-m-tolyl-1H-benzo[d]imidazole-5-yl)methanone (CID: 3243760), or 3-(2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine (CID: 2331284), or the entire disclosure thereof is incorporated herein by reference by Jadhav et al. (2011) (published in Probe Reports from the NIH Molecular Libraries Program [Internet]) as "Potent and selective inhibitors of NAD+-dependent 15-hydroxyprostaglandin It is one of the compounds disclosed in dehydrogenase(HPGD)'').
[0087] In some embodiments, the 15-PGDH inhibitor is one of the compounds disclosed in TD88, or in Seo et al. (2015) Prostaglandins, Leukotrienes and Essential Fatty Acids 97:35-41, or Shao et al. (2015) Genes & Diseases 2(4):295-298, the entire disclosure of which is incorporated herein by reference. In some embodiments, the 15-PGDH inhibitor is one of the compounds disclosed in EEAH (ethanol extract of Artocarpus heterophyllus), or in Karna (2017) Pharmacogn Mag. 2017 Jan;13 (Supplement 1):S122-S126, the entire disclosure of which is incorporated herein by reference.
[0088] inhibitory nucleic acid In some embodiments, the active agent includes inhibitory nucleic acids, such as antisense DNA or antisense RNA, small interfering RNA (siRNA), microRNA (miRNA), or small hairpin RNA (shRNA). In some embodiments, the inhibitory RNA is identical or substantially identical (e.g., at least about 70%, at least about 75%, at least about 80%, at least about 100) to a portion of the 15-PGDH polynucleotide containing a target sequence (e.g., at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 consecutive nucleotides, e.g., at least about 500, at least about 20-250, at least about 20-100, at about 50-500, or at about 50-250 consecutive nucleotides, e.g., at least about 70%, at least about 75%, at least about 80%, at least The target is a sequence that is approximately 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical (for example, the human HPGD gene, gene ID: 3248, containing any of its transcript variants as described in GenBank accession numbers NM_000860.6, NM_001145816.2, NM_001256301.1, NM_001256305.1, NM_001256306.1, NM_001256307.1, or NM_001363574.1).
[0089] In some embodiments, the methods described herein include the step of treating a subject, for example, a subject having a disease, disorder, or condition associated with joint tissue dysfunction and / or joint tissue degeneration, using shRNA or siRNA. shRNA is an artificial RNA molecule having a hairpin turn that can be used to silence target gene expression via siRNA that it generates in cells. See, for example, Fire et al., Nature 391:806-811, 1998; Elbashir et al., Nature 411:494-498, 2001; Chakraborty et al., Mol Ther Nucleic Acids 8:132-143, 2017; and Bouard et al., Br. J. Pharmacol. 157:153-165, 2009. In some embodiments, a method for treating a subject having, for example, a disease, disorder, or condition related to joint tissue degeneration such as joint tissue dysfunction and / or osteoarthritis, includes administering a therapeutically effective amount of modified RNA or vector containing a polynucleotide encoding shRNA or siRNA that can hybridize to a portion of 15-PGDH mRNA (for example, a portion of a polynucleotide sequence encoding human 15-PGDH as described in any of GenBank accession numbers NM_000860.6, NM_001145816.2, NM_001256301.1, NM_001256305.1, NM_001256306.1, NM_001256307.1 or NM_001363574.1). In some embodiments, the vector further includes appropriate expression regulatory elements known in the art, for example, a promoter (for example, an inducible promoter or a tissue-specific promoter), an enhancer, and a transcription terminator.
[0090] In some embodiments, the active agent is 15-PGDH-specific microRNA (miRNA or miR). MicroRNAs are small non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression. This is achieved by miRNA base pairing with complementary sequences within mRNA transcripts. As a result, mRNA transcripts can be silenced by one or more mechanisms, including cleavage of the mRNA strand, destabilization of the mRNA by shortening of its poly(A) tail, and reduced efficiency of translation of the mRNA transcript into proteins by ribosomes.
[0091] In some embodiments, the active agent may be an antisense oligonucleotide, such as an RNase H-dependent antisense oligonucleotide (ASO). An ASO is a single-stranded chemically modified oligonucleotide that binds to a complementary sequence in target mRNA and reduces gene expression by RNase H-mediated cleavage of the target RNA and inhibition of translation by steric blockade of ribosomes. In some embodiments, the oligonucleotide can hybridize to a portion of 15-PGDH mRNA (e.g., a portion of a polynucleotide sequence encoding human 15-PGDH as described in any of GenBank accession numbers NM_000860.6, NM_001145816.2, NM_001256301.1, NM_001256305.1, NM_001256306.1, NM_001256307.1, or NM_001363574.1). In some embodiments, the oligonucleotide has a length of approximately 10 to 30 nucleotides (e.g., approximately 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30 nucleotides). In some embodiments, the oligonucleotide has 100% complementarity with respect to the portion of the mRNA transcript to which it binds. In other embodiments, the DNA oligonucleotide has less than 100% complementarity with respect to the portion of the mRNA transcript to which it binds (e.g., approximately 95%, 90%, 85%, 80%, 75%, or 70%), but can still form a stable RNA:DNA double helix for RNase H to cleave the mRNA transcript.
[0092] Suitable antisense molecules, siRNAs, miRNAs, and shRNAs can be prepared by standard methods of oligonucleotide synthesis, or by ordering such molecules from a contract research institution or supplier by providing the targeted polynucleotide sequence. The preparation and deployment of such antisense molecules under general conditions are described in modern reference textbooks, e.g., Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 4 by N.S. Templeton. th edition;Translating Gene Therapy to the Clinic: Techniques and Approaches,1 by J. Laurence and M. Franklin st This can be achieved using the standard techniques described in *High-Throughput RNAi Screening: Methods and Protocols (Methods in Molecular Biology)* by DO Azorsa and S. Arora, and *Oligonucleotide-Based Drugs and Therapeutics: Preclinical and Clinical Considerations* by N. Ferrari and R. Segui.
[0093] Inhibitory nucleic acids can also include RNA aptamers, which are short synthetic oligonucleotide sequences that bind to proteins (see, e.g., Li et al., Nuc. Acids Res. (2006), 34:6416-24). They are noteworthy for both their high affinity and specificity to target molecules and have the additional advantage of being smaller than antibodies (usually less than 6 kD). RNA aptamers with desired specificity are commonly selected from combinatorial libraries and can be modified using methods known in the art to reduce their vulnerability to ribonucleases.
[0094] antibody In some embodiments, the active agent is an anti-15-PGDH antibody or its antigen-binding fragment. In some embodiments, the antibody is a blocking antibody (e.g., an antibody that binds to a target and directly interferes with the target's function, e.g., 15-PGDH enzyme activity). In some embodiments, the antibody is a neutralizing antibody (e.g., an antibody that binds to a target and neutralizes the downstream cellular effects of the target). In some embodiments, the antibody binds to human 15-PGDH.
[0095] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody is an antigen-binding fragment, e.g., F(ab')2, Fab', Fab, scFv, etc. The term “antibody or antigen-binding fragment” may also encompass multispecific antibodies and hybrid antibodies having dual or multiple antigen-specific or epitope-specific properties.
[0096] In some embodiments, the anti-15-PGDH antibody comprises the heavy chain sequence or a portion thereof and / or the light chain sequence or a portion thereof of the antibody sequence disclosed herein. In some embodiments, the anti-15-PGDH antibody comprises one or more complementarity-determining regions (CDRs) of the anti-15-PGDH antibody disclosed herein. In some embodiments, the anti-15-PGDH antibody is a nanobody or single-domain antibody (sdAb) comprising a single monomeric variable antibody domain, e.g., a single VHH domain.
[0097] Many techniques known in the art can be used to prepare antibodies that bind to 15-PGDH. For example, see Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp.77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2nd ed. 1986). In some embodiments, antibodies are prepared by immunizing one or more animals (e.g., mice, rabbits, or rats) with an antigen to induce an antibody response. In some embodiments, the antigen is administered in conjugation with an adjuvant (e.g., Freund's adjuvant). In some embodiments, after the initial immunization, one or more subsequent booster injections of the antigen may be administered to improve antibody production. After immunization, antigen-specific B cells are collected, for example, from the spleen and / or lymphoid tissue. To produce monoclonal antibodies, the B cells are fused with myeloma cells, which are then screened for antigen specificity.
[0098] The genes encoding the heavy and light chains of an antibody of interest can be cloned from cells; for example, the gene encoding a monoclonal antibody can be cloned from a hybridoma and used to produce recombinant monoclonal antibodies. Gene libraries encoding the heavy and light chains of monoclonal antibodies can be prepared from hybridomas or plasma cells. Furthermore, phage display or yeast display techniques can be used to identify antibodies and heteromer Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992); Lou et al., PEDS 23:311 (2010); and Chao et al., Nature Protocols 1:755-768 (2006)). Alternatively, antibodies and antibody sequences may be isolated and / or identified using yeast-based antibody-presenting systems, such as those disclosed in Xu et al., Protein Eng Des Sel, 2013, 26:663-670; International Publication No. 2009 / 036379; International Publication No. 2010 / 105256; and International Publication No. 2012 / 009568. Random combinations of heavy-chain and light-chain gene products generate a large pool of antibodies with different antigen specificities (see, e.g., Kuby, Immunology (3rd ed. 1997)). Techniques for producing single-chain or recombinant antibodies (U.S. Patent No. 4,946,778, U.S. Patent No. 4,816,567) can also be adapted to produce antibodies.
[0099] Antibodies can be produced using any number of expression systems, including prokaryotic and eukaryotic expression systems. In some embodiments, the expression system is mammalian cells such as hybridomas, or CHO cells. Many such systems are widely available from commercial suppliers. In embodiments where the antibody includes both a VH region and a VL region, the VH and VL regions may be expressed using a single vector, for example, in a disisstronic expression unit, or under the control of different promoters. In other embodiments, the VH and VL regions may be expressed using separate vectors.
[0100] In some embodiments, the anti-15-PGDH antibody comprises one or more affinity-matured CDR sequences, heavy chain sequences, and / or light chain sequences. Regarding chimeric antibodies, methods for producing chimeric antibodies are known in the art. For example, a chimeric antibody can be produced in which an antigen-binding region (heavy chain variable region and light chain variable region) from one species, such as mouse, is fused to an effector region (constant domain) from another species, such as human. Another example is the production of "class-switched" chimeric antibodies in which the effector region of an antibody is replaced by the effector region of a different immunoglobulin class or subclass.
[0101] In some embodiments, the anti-15-PGDH antibody comprises one or more humanized CDR sequences, heavy chain sequences, and / or light chain sequences. Regarding humanized antibodies, methods for producing humanized antibodies are known in the art; see, for example, U.S. Patent No. 8,095,890. Generally, humanized antibodies have one or more amino acid residues introduced from a non-human source. As an alternative to humanization, human antibodies can be produced. As a non-limiting example, transgenic animals (e.g., mice) can be produced that, upon immunization, can produce a complete repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, in chimeric mice and germline mutant mice, homozygous deletion of the antibody heavy chain binding region (JH) gene has been described as resulting in complete inhibition of endogenous antibody production. In such germline mutant mice, the transfer of a human germline immunoglobulin gene array results in the production of human antibodies upon antigen loading. For example, see Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immun., 7:33 (1993); and U.S. Patent Nos. 5,591,669, 5,589,369 and 5,545,807.
[0102] In some embodiments, antibody fragments (Fab, Fab', F(ab')2, scFv, nanobodies, or diabodies, etc.) are produced. Various techniques have been developed for the production of antibody fragments, such as protein digestion of intact antibodies (see, e.g., Morimoto et al., J. Biochem. Biophys. Meth., 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)), and the use of recombinant host cells for fragment production. For example, antibody fragments can be isolated from antibody phage libraries. Alternatively, Fab'-SH fragments can be directly recovered from E. coli (E. coli) cells and chemically conjugated to form F(ab')2 fragments (see, e.g., Carter et al., BioTechnology, 10:163-167 (1992)). By another method, F(ab')2 fragments can be directly isolated from recombinant host cell cultures. Those skilled in the art will recognize other techniques for preparing antibody fragments.
[0103] Methods for measuring binding affinity and binding kinetics are known in the art. These methods include, but are not limited to, solid-phase binding assays (e.g., ELISA assays), immunoprecipitation, surface plasmon resonance (e.g., Biacore® (GE Healthcare, Piscataway, NJ)), kinetic exclusion assays (e.g., KinExA®), flow cytometry, fluorescent cell sorting (FACS), biolayer interferometry (e.g., Octet® (ForteBio, Inc., Menlo Park, CA)), and Western blot analysis.
[0104] peptide In some embodiments, the active agent is a peptide, such as 15-PGDH, which binds to and / or inhibits the enzymatic activity or stability of 15-PGDH. In some embodiments, the active agent is a peptide aptamer. A peptide aptamer is an artificial protein selected or engineered to bind to a specific target molecule. Typically, a peptide contains one or more peptide loops of variable sequences presented by a protein backbone. Selection of peptide aptamers can be carried out using various systems, including yeast two-hybrid systems. Peptide aptamers can also be selected from combinatorial peptide libraries constructed by phage display and other surface display techniques, e.g., mRNA display, ribosome display, bacterial display, and yeast display. See, for example, Reverdatto et al., 2015, Curr. Top. Med. Chem. 15:1082-1101.
[0105] In some embodiments, the active agent is an affimer. Affimers are small, highly stable proteins, typically having a molecular weight of about 12–14 kDa, that bind to their target molecules with similar specificity and affinity as antibodies. Generally, affimers present two peptide loops and an N-terminal sequence that can be randomized to bind to a variety of target proteins with high affinity and specificity in a manner similar to monoclonal antibodies. Stabilization of the two peptide loops by the protein backbone restricts the possible conformations that the peptides can take, thereby increasing binding affinity and specificity compared to a library of free peptides. Affimers and methods for preparing them have been described in the Art. See, for example, Tiede et al., eLife, 2017, 6:e24903. Affimers are also commercially available, for example, from Avacta Life Sciences.
[0106] Vectors and Modified RNA In some embodiments, a polynucleotide that imparts 15-PGDH inhibitory activity, such as a nucleic acid inhibitor like siRNA or shRNA, or a polynucleotide encoding a polypeptide that inhibits 15-PGDH, is introduced into a cell, e.g., a tissue cell, using a suitable vector. Examples of delivery vectors that may be used with this disclosure include viral vectors, plasmids, exosomes, liposomes, bacterial vectors, or nanoparticles. In some embodiments, a polynucleotide encoding any of the 15-PGDH inhibitors described herein, e.g., a nucleic acid inhibitor or a polypeptide inhibitor, is introduced into a cell, e.g., a tissue cell, using a vector such as a viral vector. Suitable viral vectors include, but are not limited to, adeno-associated viruses (AAV), adenoviruses, and lentiviruses. In some embodiments, the polynucleotide encoding the 15-PGDH inhibitor, e.g., a nucleic acid inhibitor or a polypeptide inhibitor, is provided typically in the form of a recombinantly constructed expression cassette having a promoter operably linked to the polynucleotide sequence encoding the inhibitor. In some cases, the promoter is a universal promoter that leads to gene expression in all or most tissue types. In other cases, promoters specifically guide gene expression within cells of the target tissue.
[0107] In some embodiments, 15-PGDH nucleic acid inhibitors or protein inhibitors are introduced into a target, for example, into the target tissue, using modified RNA. It is known in the art that various modifications of RNA enhance the translation, potency, and / or stability of RNA, such as shRNA, or mRNA encoding a 15-PGDH polypeptide inhibitor, when introduced, for example, into target cells. In certain embodiments, modified mRNA (mmRNA), such as mmRNA encoding a 15-PGDH polypeptide inhibitor, is used. In other embodiments, modified RNA containing an RNA inhibitor of 15-PGDH expression, such as siRNA, shRNA, or miRNA, is used. Non-limiting examples of RNA modifications that may be used include anti-reverse cap analogs (ARCAs), e.g., poly-A tails of 100-250 nucleotides in length, substitution of AU-rich sequences in the 3'UTR with sequences derived from known stable mRNA, and modified nucleosides and structures, e.g., pseudouridines, e.g., N1-methylpsoidouridine, 2-thioidine, 4' thioRNA, 5-methylcytidine, 6-methyladenosine, amide-3 linkage, thioate linkage, inosine, 2'-deoxyribonucleotide, 5-bromouridine, and inclusion of 2'-O-methylated nucleosides. A non-limiting list of chemical modifications that may be used can be found, for example, in the online database crdd.osdd.net / servers / sirnamod / . RNA can be introduced into cells in vivo using any known method, including, among others, physical disturbance, induction of RNA endocytosis by cationic carriers, electroporation, gene guns, ultrasound, nanoparticles, conjugates, or high-pressure injection. Modified RNA can also be introduced, for example, by direct injection into citrate-buffered saline. RNA can also be delivered using self-assembled lipoplexes or polyplexes spontaneously generated by charge interactions between negatively charged RNA and cationic lipids or polymers, such as lipoplexes, polyplexes, polycations, and dendrimers.Polymers, such as poly-L-lysine, polyamidoamines and polyethyleneimines, chitosan, and poly(β-aminoesters), can also be used. See, for example, Youn et al. (2015) Expert Opin Biol Ther, Sep 2;15(9):1337-1348; Kaczmarek et al. (2017) Genome Medicine 9:60; Gan et al. (2019) Nature comm. 10:871; Chien et al. (2015) Cold Spring Harb Perspect Med. 2015;5:a014035, the entirety of each disclosure of which is incorporated herein by reference.
[0108] 8. Method of administration The compounds described herein may be administered topically or systemically to a subject. In some embodiments, the compounds may be administered directly (topically) to the joint tissue, including intra-articular (within a joint) or peri-articular (around a joint) administration by injection or direct application of the compound (or therapeutic composition containing the compound) into or around the joint tissue, for example, to improve the tissue and function of the joint. In some embodiments, the compounds may be administered systemically, including intraperitoneally, intramuscularly, intra-arterially, orally, intravenously, intracranially, intrathecally, intraspinally, intrapathologically, intranasally, subcutaneously, intraventricularly, and / or systemically by inhalation, for treatment of the structure and function of the joint tissue. In one example, the compound is administered intramuscularly, for example, by intramuscular injection.
[0109] In some embodiments, the compound is administered according to an acute regimen. In certain cases, the compound is administered to the subject once. In other cases, the compound is administered at one time point and again at a second time point. In yet another example, the compound is repeatedly administered to the subject as intermittent doses over a short period (e.g., 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, or longer) (e.g., once or twice daily). In some cases, the time between compound administrations is about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, or longer. In other embodiments, the compound is administered continuously or chronically according to a chronic regimen over a desired period. For example, the compound may be administered such that the amount or level of the compound remains substantially constant over a selected period.
[0110] The administration of compounds to subjects can be achieved by methods commonly used in the art. Factors such as sex, age, weight, type of disease, disorder, or condition, or the stage of the disease, disorder, or condition, and the amount required to produce the desired outcome may be taken into consideration. Generally, when a compound is administered for treatment purposes, cells are administered in a pharmacologically effective dose. A “pharmacologically effective dose” is defined as an amount sufficient to produce a desired physiological effect or amount that can achieve the desired outcome, particularly for treating a disease, disorder, or condition, including reducing or eliminating one or more symptoms or manifestations of the disease, disorder, or condition.
[0111] The compounds described herein may be administered locally by injection into the target joint tissue or by administration in close proximity to the target joint tissue.
[0112] 9. Pharmaceutical Compositions The pharmaceutically acceptable compositions of the compounds described herein may include a pharmaceutically acceptable carrier. In certain contexts, the pharmaceutically acceptable carrier is determined in part according to the specific composition being administered and the specific method used to administer the composition. Thus, a wide variety of suitable formulations of the pharmaceutically acceptable compositions described herein exist (see, for example, Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990)).
[0113] As used herein, “pharmaceutically acceptable carrier” includes any of the standard pharmaceutically acceptable carriers known to those skilled in the art in the formulation of pharmaceutical compositions. Accordingly, compounds can be prepared as formulations in solutions of pharmaceutically acceptable diluents, such as physiological saline, phosphate-buffered saline (PBS), aqueous ethanol, or glucose, mannitol, dextran, propylene glycol, oils (e.g., vegetable oils, animal oils, synthetic oils, etc.), microcrystalline cellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, magnesium stearate, calcium phosphate, gelatin, polysorbate 80, or as solid formulations in appropriate excipients, existing on their own, for example, as pharmaceutically acceptable salts or conjugates.
[0114] Pharmaceutical compositions often further, as needed, include one or more buffers (e.g., neutral buffered saline or phosphate-buffered saline), carbohydrates (e.g., glucose, mannose, sucrose, or dextran), mannitol, proteins, polypeptides, or amino acids (e.g., glycine), antioxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxytoluene, butylated hydroxyanisole, etc.), bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), solutes to make the formulation isotonic, hypotonic, or weakly hypertonic with the recipient's blood, suspending agents, thickeners, preservatives, flavoring agents, sweeteners, and coloring compounds.
[0115] The pharmaceutical compositions described herein are administered in a form compatible with the administered formulation and in a therapeutically effective amount. The amount administered depends on various factors, including, for example, the individual's age, weight, physical activity and diet, the disease, disorder, or condition being treated, and the stage or severity of the disease, disorder, or condition. In certain embodiments, the size of the dose may also be determined by the presence, nature, and extent of any adverse side effects associated with the administration of the therapeutic substance to a particular individual.
[0116] However, it should be understood that specific dose levels and administration frequencies for any particular patient may vary and depend on various factors, including the activity of the specific compound used, its metabolic stability and duration of action, age, weight, genetic characteristics, overall health, sex, diet, mode and timing of administration, excretion rate, drug combinations, severity of the specific condition, and the host being treated.
[0117] In certain embodiments, the dosage of the compound may take the form of a solid, semi-solid, lyophilized powder, or liquid dosage form, such as tablets, pills, pellets, capsules, powders, solutions, suspensions, emulsions, suppositories, retained enemas, creams, ointments, lotions, gels, aerosols, or foams, preferably a unit dosage form suitable for simple administration of a precise dose.
[0118] As used herein, the term “unit dosage form” refers to a physically distinct unit suitable as a single dose for humans and other mammals, each unit containing a predetermined amount of the therapeutic substance calculated to produce a desired expression, tolerability, and / or therapeutic effect in combination with a suitable pharmaceutically acceptable excipient (e.g., an ampoule). In addition, highly concentrated dosage forms may be prepared from which further diluted unit dosage forms may be produced. Thus, highly concentrated dosage forms substantially contain, for example, at least about 1x, at least about 2x, at least about 3x, at least about 4x, at least about 5x, at least about 6x, at least about 7x, at least about 8x, at least about 9x, at least about 10x, or more of the therapeutic compound.
[0119] Methods for preparing such dosage forms are known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences). The dosage forms typically include conventional pharmaceutical carriers or pharmaceutical excipients, and may further include other pharmaceuticals, carriers, adjuvants, diluents, tissue permeability enhancers, solubilizers, and the like. Suitable excipients can be adapted to specific dosage forms and routes of administration by methods well known in the art (see, for example, Remington's Pharmaceutical Sciences).
[0120] Examples of suitable excipients include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, physiological saline, syrup, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, and polyacrylic acid, e.g., Carbopol, e.g., Carbopol 941, Carbopol 980, Carbopol 981. Dosage forms may further include lubricants, e.g., talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers; suspending agents; preservatives, e.g., methyl hydroxybenzoate, ethyl hydroxybenzoate, and propyl hydroxybenzoate (e.g., parabens); pH adjusters, e.g., inorganic and organic acids and bases; sweeteners; and flavoring agents. Dosage forms may also include biodegradable polymer beads, dextran, and cyclodextrin inclusion complexes.
[0121] For oral administration, the therapeutically effective dose may be in the form of tablets, capsules, emulsions, suspensions, solutions, syrups, sprays, lozenges, powders, and sustained-release formulations. Suitable excipients for oral administration include pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, gelatin, sucrose, and magnesium carbonate.
[0122] The therapeutically effective dose may also be provided in lyophilized form. Such a dosage form may contain a buffer for reconstitution before administration, such as bicarbonate, or the buffer may be included in the lyophilized dosage form for reconstitution using, for example, water. The lyophilized dosage form may further contain a suitable vasoconstrictor, such as epinephrine. The lyophilized dosage form may optionally be provided in a syringe packaged with a buffer for reconstitution so that the reconstituted dosage form can be administered immediately to an individual.
[0123] In some embodiments, additional compounds or drugs may be administered concurrently to the subject. Such compounds or drugs may be administered concurrently for purposes such as alleviating signs or symptoms of the disease, disorder, or condition being treated, or mitigating side effects caused by the induction of an immune response. In some embodiments, for example, the 15-PGDH inhibitors described herein are administered together with compounds that enhance PGE2 levels and / or PGD2 levels, compounds that increase signaling via EP1, EP2, EP3, EP4, DP1, and / or DP2 receptors, and / or any other compounds intended to enhance joint structure and / or function, or enhance the function, health, or any other desired properties of the targeted tissue.
[0124] 10. Kit Another embodiment of the compositions described herein is a kit comprising a 15-PGDH inhibitor. The kit typically comprises containers that may be formed from a variety of materials such as glass or plastic, and may include, for example, bottles, vials, syringes and test tubes. Labels typically accompany the kit and include any documents or recorded material, which may be in electronic or computer-readable form, that provide instructions or other information for using the contents of the kit.
[0125] In some embodiments, the kit comprises one or more reagents for improving the structure and function of the joint tissue of interest. In some embodiments, the kit comprises one or more reagents for treating diseases, disorders, or conditions associated with joint tissue dysfunction and / or joint tissue degeneration, such as osteoarthritis. In some embodiments, the kit comprises an activator that antagonizes the expression or activity of 15-PGDH. In some embodiments, the kit comprises an inhibitory nucleic acid (e.g., antisense RNA, small interfering RNA (siRNA), microRNA (miRNA), small hairpin RNA (shRNA)) or polynucleotide encoding a 15-PGDH inhibitory polypeptide that inhibits or suppresses the expression or activity of 15-PGDH mRNA or protein, e.g., enzyme activity. In some embodiments, the kit comprises modified RNA, e.g., modified shRNA or modified siRNA, or modified mRNA encoding a polypeptide 15-PGDH inhibitor. In some embodiments, the kit further comprises one or more plasmids, bacterial vectors, or viral vectors for the expression of an inhibitory nucleic acid or polynucleotide encoding a 15-PGDH inhibitory polypeptide. In some embodiments, the kit includes an antisense oligonucleotide that can hybridize to a portion of the mRNA encoding 15-PGDH. In some embodiments, the kit includes an antibody (e.g., a monoclonal antibody, polyclonal antibody, humanized antibody, bispecific antibody, chimeric antibody, blocking antibody, or neutralizing antibody) or an antibody-binding fragment that specifically binds to and inhibits the 15-PGDH protein. In some embodiments, the kit includes a blocking peptide. In some embodiments, the kit includes an aptamer (e.g., a peptide aptamer or a nucleic acid aptamer). In some embodiments, the kit includes an affimer. In some embodiments, the kit includes modified RNA. In certain embodiments, the kit includes a small molecule inhibitor that binds to or inhibits the enzymatic activity of 15-PGDH, e.g., SW033291. In some embodiments, the kit further includes one or more additional therapeutic agents, e.g., agents for administration in combination therapy with agents that antagonize the expression or activity of 15-PGDH.
[0126] In some embodiments, the kit may further include instructional materials (e.g., protocols) for carrying out the methods described herein (e.g., instructions for using the kit to improve the structure and / or function of the joint tissue in question, and / or for treating diseases, disorders, or conditions associated with joint tissue degeneration such as joint tissue dysfunction and / or osteoarthritis; and / or for using the kit to enhance the function, health, or other properties of non-skeletal muscle tissue). The instructional materials typically include, but are not limited to, documents or printed materials. Any medium capable of storing such instructions and communicating them to end users is contemplated by this disclosure. Such mediums include, but are not limited to, electronic storage media (e.g., magnetic disks, tapes, cartridges, chips), optical media (e.g., CD-ROMs), and the like. Such mediums may include addresses to internet sites providing such instructional materials. [Examples]
[0127] The present disclosure will be further described with specific examples. The following examples are provided for illustrative purposes only and are not intended to limit the present disclosure. Those skilled in the art will readily recognize various non-essential parameters that can be changed or modified to produce essentially the same results.
[0128] Example 1. Materials and methods used in the example. Mouse handling.All experiments and protocols were conducted in accordance with the facility guidelines of Stanford University and the Administrative Panel on Laboratory Animal Care (APLAC). Aged (24-28 month) mice C57BL / 6 were obtained from the aging colony of the US National Institute on Aging (NIA). Mice were treated once daily for one month by intraperitoneal injection of either 5 mg / kg of SW033291 (SW) (ApexBio catalog number A8709) or a vehicle consisting of 10% ethanol, 5% Cremophor EL (Sigma-Aldrich catalog number C5135), and 85% D5W (5% dextrose water). Three independent studies of aged mice were conducted using either vehicle treatment or SW treatment. Mice that developed dermatitis throughout the treatment period or that showed visible tumors at endpoint necropsy were excluded from the studies. Young (3-month-old) wild-type C57BL / 6 mice were obtained from Jackson Laboratory (n=8 per group). Male mice were used in the studies.
[0129] Tibial loading to induce osteoarthritis in young mice In summary, mice were anesthetized using 2.5% isoflurane inhalation under 4 L / min of oxygen. The right tibia was positioned vertically, the ankle superior, the knee inferior, and deeply flexed between loading cups. Using a material testing machine (Instron ElectroPulse E1000), axial compression was applied through the knee via the upper cup while the lower cup was fixed and connected to a load cell. ACL rupture was confirmed by the release of the compressive force during compression. Mice were allowed to progress for 6 weeks after loading (n=8 for each group). The contralateral left limb functioned as a non-loading control. Mouse serum was collected via posterior orbital hemorrhage and subjected to multiple autoantibody assays. Mice were euthanized by cervical dislocation, and the knee joint was collected for evaluation.
[0130] Harvesting and processing of human cartilage tissue.Human cartilage samples were collected from surgical knee tissue waste of patients (n>5, aged 55–75 years) undergoing total knee replacement, following an approved institutional review board protocol for human subjects at Stanford University. Written informed consent was obtained from patients prior to the study. Cylindrical explants (4 mm in diameter, 2–4 mm thick) were extracted from the cartilage samples using a standard biopsy punch (Integra, NJ, USA). Prior to the experiment, 25 μg mL of 10% fetal bovine serum (FBS) was administered. -1 Cartilage explants were cultured in DMEM-F12 medium supplemented with ascorbic acid, 1× glutamine, and 1× antibiotic-antifungal solution. To evaluate the effect of 15-PGDH inhibition, the explants were treated with vehicle (DMSO) or SW (10 μM) for one week prior to evaluation. Fresh medium was added to the explants every other day.
[0131] Histological examination of mouse joints and human cartilage explants. Mouse joints were fixed overnight in 4% paraformaldehyde, dehydrated in ethanol, and embedded in paraffin. Sagittal sections (5 μm) of mouse joints were cut by Histoserv, Inc. (Germantown, MD). As previously reported (Smeriglio et al., 2020, Sci Transl. Med. 12:eaax2332), cartilage histological examination was performed by safranin O (Saf O) staining. Joints were evaluated by blind grading using the OARSI scoring system. In summary, cartilage degeneration was evaluated by staining mouse joint sections with safranin O and assigning numbers 0-4 to increase the depth of cartilage degeneration (OARSI scoring system). For the summit score, five regions were totaled.
[0132] After treatment with SW for one week, the explants were fixed in 4% paraformaldehyde, washed with PBS, and frozen overnight in 30% sucrose solution. The explants were then embedded in Tissue-Tek OCT medium and sectioned using Leica Cryostat (approximately 10 μm thick). Sections were stained with hematoxylin (Sigma) for nuclear visualization, and proteoglycans were stained with safranin O (catalog no. 731 583, Sigma) and counterstained with Fast Green (catalog no. F7258, Sigma). Sections were visualized at 20x magnification using a Keyence microscope. Explants obtained from at least five different patient donors and multiple (>5) sections were used for quantitative analysis.
[0133] Luminex assay This assay was performed at the Human Immune Monitoring Center at Stanford University. Human 76-plex kits or mouse 48-plex kits (eBioscience / Affymetrix) were used according to the manufacturer's recommendations. In summary, antibody beads and samples were added to a 96-well plate and incubated at room temperature for 2 hours, followed by overnight incubation at 4°C with shaking at 500–600 rpm. The plate was then washed in washing buffer, and biotinylated detection antibody was added over 2 hours at room temperature with shaking. The plate was washed again, and streptavidin-phycoerythrin was added. After 40 minutes of incubation and washing, reading buffer was added to the wells. Using a Luminex 200 instrument, the plate was read to a lower limit of 50 beads / sample per cytokine. Custom assay control beads were added to all wells. Raw MFI readings of all samples were used and analyzed by GraphPad prism.
[0134] RNA extraction and library preparation from mouse joints for RNA sequencing.Microscopic dissection of the knee joint was performed under stereoscopic guidance, and tendons, synovial membrane, and meniscal residue were carefully removed. Cartilage tissue was then collected by thinly shaving the cartilage tissue from the underlying bone (Smeriglio et al., 2020, Sci Transl. Med. 12:eaax2332). Subsequently, the isolated cartilage tissue was preserved in RNA (Ambion) and stored at -80°C for later use. The cartilage tissue was homogenized in Trizol using a bullet blender (Next Advance), and then RNA extraction and purification were performed using the RNeasy microkit (Qiagen). A cDNA library was constructed from 10 ng of total RNA using the SMARTer stranded Total RNA-Seq kit v3 (Takara Bio). Using the Illumina NovaSeq platform (Novogene, CA), 25-30 × 10⁶ samples were scanned. 6 The library was sequenced using individual 150bp paired-end reads.
[0135] Differential gene expression analysis. For RNA-seq analysis, transcript expression was quantified using the pseudo-aligner Salmon. Sequences were then aligned to the Mus musculus genome (mm9) using the STAR aligner. A count matrix containing the counts for each gene and each sample was obtained. This matrix was analyzed by DESeq2 to calculate statistical analysis of gene significance between samples. Upregulated or downregulated genes with p-values and change factor cutoffs of 0.05 and 2, respectively, were used. Functional analysis of differentially expressed genes was performed using Ingenuity pathway analysis (IPA) and the DAVID bioinformatics tool.
[0136] Transmission electron microscopy (TEM).The knee joint was fixed at 4°C for 4 hours in Karnovsky fixative, which consisted of 2% glutaraldehyde (EMS catalog number 16000) and 4% paraformaldehyde (EMS catalog number 15700) in 0.1M sodium cacodylate (EMS catalog number 12300) pH 7.4. The joint was washed three times with cold PBS and then decalcified in PBS solution of 14% EDTA at 4°C for 3 days. The sample was washed with PBS and placed in 1% cold / aqueous osmium tetroxide (EMS catalog number 19100) on a rotator and warmed to room temperature (RT) for 1 hour. The sample was washed three times with ultrafiltered water and then stained in 1% uranyl acetate at room temperature for 2 hours. The sample was then dehydrated by a series of ethanol washes, starting at 50% and 70%, for 30 minutes each at room temperature, and finally allowed to rise overnight to 4°C. These were placed in cold 95% EtOH, heated to room temperature, converted to 100% 2×, and then immersed in propylene oxide (PO) for 15 minutes. The samples were then impregnated with EMbed-812 resin (EMS catalog number 14120) mixed with PO in a 1:2, 1:1, and 2:1 ratio for 2 hours each, leaving the samples in the 2:1 resin-to-PO mixture and rotating overnight at room temperature in a hood. The samples were then immersed in EMbed-812 for 2-4 hours, then placed in a mold containing labels and fresh resin, oriented, and baked overnight in a 65°C oven.
[0137] Next, 80 nm sections were cut on a 100-mesh Cu grid coated with formvar / carbon using UC7 (Leica, Wetzlar, Germany), stained in a 50% acetone solution of 3.5% uranyl acetate for 40 seconds, and then stained in Sato's lead citrate for 2 minutes. The sections were then observed using a JEOL JEM-1400 120 kV transmission electron microscope. Images were acquired using a Gatan Orius 832 4k×4k with a 9 μm pixel CMOS camera.
[0138] 1,9-dimethylmethylene blue (DMMB) and Pico-green assay.Human OA cartilage explants (n ≥ 3 / donor, and at least 5 donors) were treated with vehicle or SW (10 μM) for 7 days. Thereafter, the explants were weighed and digested overnight at 65 °C in papain digestion buffer (5 mM l-cysteine, 100 mM Na2HPO4, 5 mM EDTA, 125 μg mL[[ID=I]] -1 papain, pH 7.5). After digestion, the samples were centrifuged at 21,000 x g for 5 minutes at room temperature. Then, the supernatant was used for DMMB and Pico-green assays to estimate the sulfated glycosaminoglycan (sGAG) content in OA cartilage explants according to the published protocol (Sahu et al., 2021, Adv. Healthc. Mater. 10: e2002118). Briefly, 20 μL of the sample was mixed with 200 μL of DMMB solution (0.03 m NaCl, 40 mm glycine, 9.5% 0.1 m acetic acid, 16 mg of DMMB dye dissolved in aqueous solution, pH 3.0), and the absorbance was immediately measured at 525 nm. Chondroitin-4 sulfate was used as a standard. The same papain digestion supernatant of OA explants was used to measure the DNA content in OA explants by Pico-green assay (Quant-iT Pico-green dsDNA Assay Kit, Invitrogen) according to the manufacturer's instructions. The quantified sulfated GAG content in OA cartilage explants was normalized to the weight and DNA content of the corresponding explants.
[0139] Immunostaining of the cell cycle marker Ki67.Human OA explants treated with vehicle and SW were fixed and embedded in OCT as described in the previous section. Using a cryostat, 10 μm sections were obtained on poly-l-lysine coated glass slides. Immunostaining was performed using a standard protocol. In summary, tissue sections were permeabilized with 0.25% Triton X-100 for 10 minutes and washed with PBS. Proteinase-K treatment was also performed for 10 minutes to remove antigen masking. The sections were then washed and blocked with 2% goat serum at room temperature for 2 hours. After blocking, the sections were incubated overnight at 4°C with primary antibody and anti-human Ki67 antibody (1:100, catalog no. 14-5699-82, eBioscience). After primary antibody incubation, the slides were washed three times in PBS and incubated with goat anti-mouse Alexa fluor 546 secondary antibody at a 1:250 dilution for 1 hour at room temperature. Next, wash the slides with PBS and add Hoechst 33342 (2 μg mL). -1 The samples were incubated in (catalog number H3570, Invitrogen) for 15 minutes and then mounted using an aqueous mounting medium. The stained sections were visualized under a confocal microscope (Leica) at 63x magnification. Image analysis was performed using ImageJ.
[0140] Example 2. In aging mice, systemic 15-PGDH inhibition by small molecule treatment regenerates cartilage. To investigate whether cartilage degeneration observed in age-related (or osteoarthritis) joints could be overcome by systemic delivery of a small molecule inhibitor of 15-PGDH, a cohort of 24-month-old aged mice was intraperitoneally treated with SW033291 (SW) or a vehicle (Figure 1, upper panel). SW has been previously and extensively characterized in vitro as a specific inhibitor of 15-PGDH (ki of 0.1 nM). In vivo, SW doubled PGE2 levels in the bone marrow, colon, lung, and liver, and also increased PGD2 levels to a lesser extent, which was shown to enhance post-injury regeneration of these tissues in juvenile mice (Zhang et al., 2015, Science 348:aaa2340). After one month of daily intraperitoneal SW treatment, the 15-PGDH specific activity was significantly reduced in aging muscle, and LC-MS / MS detected an associated increase in PGE2 and PGD2 levels comparable to that in juvenile muscle (Palla et al., 2021, Science 371:eabc8059).
[0141] Histological examination of the knee joints of these mice revealed extensive cartilage degeneration in aging mice treated with vehicle controls. Representative images of mouse knee joints stained with safranin O, with cartilage proteoglycans (GAGs) stained, showed age-related decrease in GAG staining, decreased cartilage thickness, and increased fibrosis. However, after daily intraperitoneal injection of SW033291, the joints of aging mice showed improved cartilage structure with increased thickness, increased GAG staining, and increased smoothness of the cartilage surface (Figure 1, lower left panel). Based on the OARSI scoring system, blinded scoring of mouse knee joints after control or SW treatment (Glasson et al., 2010, Osteoarthritis Cartilage 18 suppl.3:S17-23) showed that the maximum injury score, maximum score, and cumulative summit score were significantly reduced in SW-treated mouse knee joints compared to control-treated mice (Figure 1, lower right panel). These results clearly demonstrated that SW-mediated inhibition of 15-PGDH can inhibit age-related osteoarthritis in a cohort of 18 independent mice.
[0142] Example 3. Local 15-PGDH inhibition in the knee by intra-articular SW injection attenuates post-traumatic osteoarthritis in adult mice. To test whether 15-PGDH inhibition is protective in relatively young adult mice when inducing osteoarthritis (OA), OA was induced in young adult mice (3 months old) by applying tibial compression to the mouse knee to induce anterior cruciate ligament (ACL) rupture. This injury model replicates ACL injury frequently observed in human patients. One week after injury, the mice were administered topically via intra-articular injection of vehicle or SW twice weekly for 4 weeks. After 6 weeks, the mice were euthanized and the knee joints were harvested (experimental scheme shown in the upper left panel of Figure 2). Safranin O staining of the mouse knee joints showed reduced GAG staining and cartilage degradation in vehicle-injected mice (Figure 2, upper right panel, top row), while SW-injected mice showed higher GAG staining and reduced cartilage degradation (Figure 2, upper right panel, bottom row). Based on the OARSI scoring system, during blinded scoring of mouse knee joints, the maximum injury score, maximum score, and cumulative summit score were observed to be significantly reduced in mouse knee joints after SW injection compared to vehicle injection (Figure 2, lower left panel). To assess inflammation in these mice, serum obtained from vehicle or SW-injected mice was tested for the 39-plex Luminex cytokine panel. Compared to vehicle-treated mice, SW showed an overall decrease in inflammatory cytokine levels, with significant downregulation of CCL7, CXCL10, CCL4, VEGF, IL27, and IL2 (Figure 2, lower right panel). These observations support the idea that local 15-PGDH inhibition by SW treatment not only enhances cartilage regeneration but also reduces inflammation in osteoarthritis mice.
[0143] Example 4. 15-PGDH inhibition rejuvenates cartilage in aging mice by altering multiple pathways. To identify the downstream molecular pathways through which 15-PGDH exerts its effects on aging cartilage, transcriptome analysis was performed on vehicle- and SW-treated cartilage obtained from aging mice (24 months), and compared with cartilage obtained from young adult mice (3 months) by RNA-seq. Figure 3 shows heatmaps of differentially expressed genes (DEGs) between the three groups, namely young cartilage and vehicle- or SW-treated aging cartilage. Compared to vehicle-treated aging cartilage, 147 out of 301 differentially expressed genes (DEGs) were upregulated and 154 were downregulated in SW-treated aging cartilage. Table 1 shows the Ingenuity Pathway Analysis (IPA) for significantly altered pathways in the cartilage of aging mice systemically treated with vehicle or SW. Table 2 shows the IPA for significantly altered pathways in the cartilage of young mice and vehicle-treated aging mice. Table 3 shows the mean and standard deviation ("STD") of significantly altered genes associated with the mitochondrial oxidative phosphorylation pathway identified in Tables 1 and 2. Table 4 shows the mean and standard deviation ("STD") of significantly altered genes associated with the osteoarthritis pathway identified in Tables 1 and 2. IPA revealed significant upregulation of genes involved in mitochondrial function and metabolism in SW-treated cartilage (Table 1). COX5a and Ndufa9, enzymes crucial for mitochondrial function and energy production, were found to be significantly upregulated in SW-treated cartilage to levels nearly the same as those observed in young cartilage (Table 3). In contrast, pathways / genes involved in mitochondrial dysfunction and osteoarthritis were significantly upregulated in vehicle-treated aging cartilage compared to young cartilage (Tables 2 and 4). These observations indicate that 15-PGDH inhibition by SW treatment affects multiple pathways for rejuvenating aging cartilage to a relatively younger phenotype.
[0144] (Table 1) Enriched pathways in SW-treated aging mice compared to vehicle-treated aging mice. TIFF2023552832000002.tif47128
[0145] (Table 2) Enriched pathways in vehicle-treated aging mice compared to young mice TIFF2023552832000003.tif47128
[0146] (Table 3) Changes in oxidative phosphorylation-related genes TIFF2023552832000004.tif56146
[0147] (Table 4) Change ratio of osteoarthritis-related genes TIFF2023552832000005.tif56146
[0148] Example 5. 15-PGDH inhibition enhances mitochondrial biosynthesis in aging cartilage. Since 15-PGDH inhibition in aging cartilage resulted in upregulation of genes and pathways related to mitochondrial biosynthesis, we directly investigated mitochondrial biosynthesis in young and aging chondrocytes within the articular cartilage of mouse knee joints. Transmission electron microscopy (TEM) images revealed a significant decrease in the total number of mitochondria per cell in aging cartilage (24-month-old mice) compared to young cartilage (3-month-old mice) (Figure 4, upper panel). Interestingly, histological sections of SW-treated aging cartilage showed a significant increase in the number of mitochondria per cell compared to vehicle-treated aging cartilage (Figure 4, upper panel). Quantification of mitochondria per cell using ImageJ software showed that these changes were significant in SW-treated cells, restoring the number of mitochondria in aging chondrocytes to the level of young cartilage (Figure 4, lower panel).
[0149] Example 6. 15-PGDH inhibition in human OA cartilage explants induces a regenerative response and reduces inflammation. Next, the effect of 15-PGDH inhibition on human osteoarthritis cartilage was tested. Human articular cartilage was isolated from surgically discarded femoral heads of patients undergoing total knee arthroplasty under the IRB protocol approved by Stanford University. OA cartilage explants of similar size, 4 mm in diameter, were punched out and cultured as previously described (Sahu et al., 2021, Adv. Healthc. Mater. 10:e2002118). OA explants were treated with vehicle or SW for 1 week. Proteoglycan content in cartilage explant sections was assessed by safranin O staining, and increased GAG staining was observed across all different regions of the cartilage, particularly the intermediate and deep regions, after SW treatment (Figure 5, upper left panel). Sulfated glycosaminoglycans (sGAGs) were also independently quantified by measurement using DMMB dye. The GAG content measured by this biochemical assay was observed to be significantly increased in human explants treated with SW compared to those treated with the vehicle (Figure 5, upper right panel). Next, the effect of SW treatment on cell proliferation was investigated. Immunostaining with the cell cycle marker Ki67 showed an increase in Ki67-positive cells in SW compared to vehicle-treated explants (Figure 5, lower panel). This increase was also supported by a Ki67 intensity distribution plot showing increased Ki67 expression in SW compared to vehicle-treated cells (Figure 6, upper panel). Next, to test the effect of 15-PGDH inhibition on inflammation, cytokine levels in the culture medium of vehicle-treated human OA explants or SW-treated human OA explants were evaluated using the 72-plex Luminex cytokine panel. In the secretome of SW-treated explants, a significant decrease in GMCSF, IL6, and CCL5 levels was observed (Figure 6, lower panel), indicating that SW treatment of human OA cartilage also resulted in a reduction of inflammatory cytokines, similar to that in mice.
[0150] While the foregoing disclosures are described in some detail as examples and illustrations to clarify understanding, those skilled in the art will understand that certain changes and modifications may be made within the scope of the appended claims. Furthermore, each reference provided herein is incorporated by reference to the same extent as each individual reference is incorporated by reference.
[0151] Exemplary aspects Exemplary embodiments provided in accordance with the subject matter of this disclosure include, but are not limited to, the claims and the following embodiments. Embodiment 1: A method for improving the structure and / or function of joint tissue of a subject, comprising the step of administering to the subject an amount of a 15-PGDH inhibitor effective in inhibiting 15-hydroxyprostaglandin (15-PGDH) activity and / or lowering 15-PGDH levels in the subject, thereby improving the structure and / or function of the joint tissue of the subject. Embodiment 2: The method of Embodiment 1, wherein the administration increases the levels of prostaglandin E2 (PGE2) and / or prostaglandin D2 (PGD2) in the joint tissue of the subject. Embodiment 3: The method of Embodiment 2, wherein the levels of PGE2 and / or PGD2 in the joint tissue are increased compared to the joint tissue before administration of the 15-PGDH inhibitor. Embodiment 4: Any method of Embodiments 1 to 3, wherein the target joint tissue presents at least one marker of dysfunction and / or degeneration. Embodiment 5: The method of Embodiment 4, wherein the at least one marker is selected from the group consisting of decreased GAG staining, decreased cartilage thickness, increased fibrosis, decreased cartilage surface smoothness, decreased bone tissue density, increased OARSI score, decreased sGAG level, decreased cell proliferation, increased pain and / or pain-related behavior in the subject, increased Indian hedgehog (Ihh) protein expression, increased catabolic gene expression, decreased anabolic chondrocyte gene expression, decreased expression of genes involved in mitochondrial function and metabolism, increased expression of genes involved in mitochondrial dysfunction and / or osteoarthritis, decreased mitochondrial biosynthesis, decreased mitochondrial levels, increased type X collagen levels, increased chondrocyte size, increased chondrocyte sphericity, increased cytokine and / or chemokine levels, increased inflammatory mediator levels, increased cell-derived products and / or matrix-derived products, and combinations thereof. Embodiment 6: The method of Embodiment 4 or 5, wherein the administration reduces at least one marker of joint tissue dysfunction and / or degeneration. Embodiment 7: Any method of Embodiments 4 to 6, wherein the dysfunction and / or degeneration of the joint tissue is a result of aging. Embodiment 8: Any method of Embodiments 4 to 6, wherein the dysfunction and / or degeneration of the joint tissue is a result of injury. Embodiment 9: The method of Embodiment 8, wherein the injury is selected from the group consisting of cartilage injury, joint injury, trauma, anterior cruciate ligament (ACL) rupture, meniscus tear, hip labral tear, rotator cuff injury, spondylosis, vertebral fracture, hip fracture, degenerative spondylolisthesis, spondylolisthesis, herniated disc, and combinations thereof. Embodiment 10: The method according to any one of Embodiments 4 to 6, wherein the dysfunction and / or degeneration of the joint tissue is a result of a disease, disorder, or pathological condition. Embodiment 11: The method of Embodiment 10, wherein the disease, disorder, or pathological condition is selected from the group consisting of osteoarthritis, other types of arthritis, osteoporosis, rheumatoid arthritis, juvenile idiopathic arthritis, gout, systemic lupus erythematosus, seronegative spondyloarthropathy, degenerative disc disease, congenital cartilage disorders, bone disorders, and combinations thereof. Embodiment 12: The method of Embodiment 10, wherein the disease, disorder, or pathological condition is osteoarthritis. Embodiment 13: Any method of Embodiments 4 to 12, wherein the levels of PGE2 and / or PGD2 in the joint tissue increase to a level substantially similar to that present in the joint tissue of the subject which does not exhibit the at least one marker of dysfunction and / or degeneration. Embodiment 14: Any method of Embodiments 4 to 13, wherein the levels of PGE2 and / or PGD2 in the joint tissue are increased to a level within 10% to 200% of the level present in the joint tissue of the subject that does not exhibit the at least one marker of dysfunction and / or degeneration. Embodiment 15: The method according to any one of Embodiments 1 to 14, wherein the joint tissue is selected from the group consisting of cartilage, synovial membrane, bone, bone marrow, ligament, tendon, bursa, meniscus, and combinations thereof. Embodiment 16: A method according to any one of Embodiments 1 to 15, wherein the structure and / or function of the joint tissue is improved compared to the joint tissue before administration of the 15-PGDH inhibitor. Embodiment 17: Any method of Embodiments 1 to 16, resulting in increased GAG staining, increased cartilage thickness, decreased fibrosis, increased smoothness of the cartilage surface, increased bone tissue density, decreased OARSI score, increased sGAG levels, increased cell proliferation, decreased pain and / or pain-related behavior in the subject, decreased Indian hedgehog (Ihh) protein expression, decreased catabolic gene expression, increased anabolic chondrocyte gene expression, increased expression of genes involved in mitochondrial function and metabolism, decreased expression of genes involved in mitochondrial dysfunction and / or osteoarthritis, increased mitochondrial biosynthesis, increased mitochondrial levels, decreased X-collagen levels, decreased chondrocyte size, decreased chondrocyte sphericity, decreased cytokine and / or chemokine levels, decreased inflammatory mediator levels, decreased cell-derived products and / or matrix-derived products, or any combination thereof. Embodiment 18: Any method of Embodiments 1 to 17, which results in a decrease in the levels of PGE2 and / or PGD2 metabolites in the joint tissue compared to the joint tissue before administration of the 15-PGDH inhibitor. Embodiment 19: A method according to any of Embodiments 4 to 18, which results in levels of PGE2 and / or PGD2 metabolites in joint tissue that are substantially similar to those present in joint tissue of a subject that does not exhibit the at least one marker of dysfunction and / or degeneration. Embodiment 20: The method of Embodiment 18 or 19, wherein the PGE2 and / or PGD2 metabolites are selected from the group consisting of 15-ketoPGE2 and 13,14-dihydro-15-ketoPGE2. Embodiment 21: The method according to any one of Embodiments 1 to 20, wherein the 15-PGDH inhibitor is selected from the group consisting of small molecule compounds, blocking antibodies, nanobodies, and peptides. Embodiment 22: The method according to any one of Embodiments 1 to 21, wherein the 15-PGDH inhibitor is SW033291. Embodiment 23: The method according to any one of Embodiments 1 to 20, wherein the 15-PGDH inhibitor is selected from the group consisting of antisense oligonucleotides, microRNAs, siRNAs, and shRNAs. Embodiment 24: Any method according to Embodiments 1 to 23, wherein the subject is a human. Embodiment 25: Any of the methods described in Embodiments 1 to 24, wherein the subject is under 30 years of age. Embodiment 26: Any of the methods in Embodiments 1 to 24, wherein the subject is at least 30 years old. Embodiment 27: Any method of Embodiments 1 to 26, wherein the 15-PGDH inhibitor reduces or blocks 15-PGDH expression. Embodiment 28: The method according to any of Embodiments 1 to 27, wherein the 15-PGDH inhibitor reduces or blocks the enzymatic activity of 15-PGDH.
Claims
1. A composition for improving the structure and / or function of a subject's joint tissue, comprising a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor in an amount effective to inhibit 15-PGDH activity and / or reduce 15-PGDH levels in a subject, thereby improving the structure and / or function of the subject's joint tissue.
2. Prostaglandin E in the joint tissue of the subject 2 (PGE2) and / or prostaglandin D 2 The composition of claim 1, wherein the level of (PGD2) is increased.
3. 3. The composition of claim 1 or 2, wherein the levels of PGE2 and / or PGD2 in the joint tissue are increased compared to the joint tissue before administration of the 15-PGDH inhibitor.
4. The composition of any one of claims 1 to 3, wherein the subject's joint tissue exhibits at least one marker of dysfunction and / or degeneration.
5. 5. The composition of claim 4, wherein the at least one marker is selected from the group consisting of decreased GAG staining, decreased cartilage thickness, increased fibrosis, decreased smoothness of the cartilage surface, decreased bone tissue density, increased OARSI score, decreased levels of sGAG, decreased cell proliferation, increased pain and / or pain-related behaviors in the subject, increased expression of Indian Hedgehog (Ihh) protein, increased expression of catabolic genes, decreased expression of anabolic chondrocyte genes, decreased expression of genes involved in mitochondrial function and metabolism, increased expression of genes involved in mitochondrial dysfunction and / or osteoarthritis, decreased mitochondrial biogenesis, decreased mitochondrial levels, increased levels of type X collagen, increased chondrocyte size, increased chondrocyte sphericity, increased levels of cytokines and / or chemokines, increased levels of inflammatory mediators, increased levels of cell-derived products and / or matrix-derived products, and combinations thereof.
6. A composition described in claim 4 or 5, wherein at least one marker of joint tissue dysfunction and / or degeneration is reduced.
7. The composition according to any one of claims 4 to 6, wherein said joint tissue dysfunction and / or degeneration is a result of aging.
8. The composition according to any one of claims 4 to 6, wherein said joint tissue dysfunction and / or degeneration is the result of injury.
9. 9. The composition of claim 8, wherein the injury is selected from the group consisting of cartilage injury, joint injury, trauma, anterior cruciate ligament (ACL) tear, meniscus tear, hip labrum tear, rotator cuff injury, spondylosis, spinal fracture, hip fracture, degenerative spondylolisthesis, slipped disc, herniated disc, and combinations thereof.
10. The composition of any one of claims 4 to 6, wherein the dysfunction and / or degeneration of the joint tissue is the result of a disease, disorder or pathology.
11. 11. The composition of claim 10, wherein the disease, disorder, or condition is selected from the group consisting of osteoarthritis, other types of arthritis, osteoporosis, rheumatoid arthritis, juvenile idiopathic arthritis, gout, systemic lupus erythematosus, seronegative spondyloarthropathy, degenerative disc disease, congenital cartilage disorders, bone disorders, and combinations thereof.
12. 11. The composition of claim 10, wherein the disease, disorder, or condition is osteoarthritis.
13. The composition of any one of claims 4 to 12, wherein the levels of PGE2 and / or PGD2 in said articular tissue are increased to levels substantially similar to those present in articular tissue of a subject that does not exhibit said at least one marker of dysfunction and / or degeneration.
14. The composition of any one of claims 4 to 12, wherein the levels of PGE2 and / or PGD2 in said articular tissue are increased to a level within 10% to 200% of the level present in articular tissue of a subject that does not display said at least one marker of dysfunction and / or degeneration.
15. The composition of any one of claims 1 to 14, wherein the articular tissue is selected from the group consisting of cartilage, synovium, bone, bone marrow, ligament, tendon, bursa, meniscus, and combinations thereof.
16. The composition according to any one of claims 1 to 15, wherein the structure and / or function of the joint tissue is improved compared to the joint tissue before administration of the 15-PGDH inhibitor.
17. 17. The composition of any one of claims 1-16, wherein the following is achieved: increased GAG staining, increased cartilage thickness, decreased fibrosis, increased smoothness of cartilage surface, increased bone tissue density, decreased OARSI score, increased levels of sGAG, increased cell proliferation, decreased pain and / or pain related behaviors in said subject, decreased expression of Indian Hedgehog (Ihh) protein, decreased expression of catabolic genes, increased expression of anabolic chondrocyte genes, increased expression of genes involved in mitochondrial function and metabolism, decreased expression of genes involved in mitochondrial dysfunction and / or osteoarthritis, increased mitochondrial biogenesis, increased mitochondrial levels, decreased levels of collagen type X, decreased chondrocyte size, decreased chondrocyte sphericity, decreased levels of cytokines and / or chemokines, decreased levels of inflammatory mediators, decreased levels of cell-derived products and / or matrix-derived products, or any combination thereof.
18. The composition of any one of claims 1 to 17, wherein the levels of PGE2 and / or PGD2 metabolites in the joint tissue are reduced compared to the joint tissue before administration of the 15-PGDH inhibitor.
19. 19. The composition of claim 18, wherein the PGE2 and / or PGD2 metabolite is selected from the group consisting of 15-ketoPGE2 and 13,14-dihydro-15-ketoPGE2.
20. A composition described in any one of claims 4 to 19, wherein the levels of PGE2 and / or PGD2 metabolites in articular tissue are substantially similar to the levels present in articular tissue of a subject that does not exhibit at least one of the markers of dysfunction and / or degeneration.
21. The composition of claim 20, wherein the PGE2 and / or PGD2 metabolite is selected from the group consisting of 15-ketoPGE2 and 13,14-dihydro-15-ketoPGE2.
22. The composition of any one of claims 1 to 21, wherein the 15-PGDH inhibitor is selected from the group consisting of a small molecule compound, a blocking antibody, a nanobody, and a peptide.
23. The composition of any one of claims 1 to 22, wherein the 15-PGDH inhibitor is SW033291.
24. The composition of any one of claims 1 to 21, wherein the 15-PGDH inhibitor is selected from the group consisting of an antisense oligonucleotide, a microRNA, an siRNA, and an shRNA.
25. The composition of any one of claims 1 to 24, wherein the subject is a human.
26. The composition of any one of claims 1 to 25, wherein the subject is under 30 years of age.
27. The composition of any one of claims 1 to 25, wherein the subject is at least 30 years of age.
28. The composition of any one of claims 1 to 27, wherein the 15-PGDH inhibitor reduces or blocks 15-PGDH expression.
29. The composition of any one of claims 1 to 28, wherein the 15-PGDH inhibitor reduces or blocks the enzymatic activity of 15-PGDH.
